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ethanol-fed rats. The concentrations of dopamine and DOPAC 
were increased two-fold in the frontal cortex, ventral 
pallidum, and ventral tegmental area, while the levels were 
unchanged in the striatum and globus pallidus. In the 
substantia nigra, the dopamine level was decreased and the 
level of DOPAC was increased. Although the dopamine level in 
the nucleus accumbens was normal, the level of DOPAC was 
decreased. An analysis of the G proteins, Gs and Go, 
demonstrated minimal, if any, changes in either protein 
content and mRNA levels in brain regions analyzed. 
Concerning the inhibitory G proteins, the mRNA levels of Gi1 
and Gi2 were unchanged in all brain regions examined. 
However, there was a trend towards an increase in the mRNA 
levels of Gi3 in all regions except the substantia nigra. In 
the frontal cortex and striatum, no change was seen in 
dopamine-sensitive adenylate cyclase activity. Adenylate 
cyclase activity in the presence of dopamine was 
significantly increased in the nucleus accumbens of 
ethanol-treated rats. In comparison to control animals, 
there was an increase in cholesterol levels, while the 
levels of phospholipids were not significantly different. 
There was also an increase in the ratio of cholesterol to 
phospholipid. 
These results suggest a selective ethanol effect on 
several components of the dopamine system in three-month-old 
Fisher 344 rats following one month of ethanol consumption. 
iv 
Those brain regions which are affected are associated with 
the mesolimbic dopamine pathway. The changes in the brain 
regions of the mesolimbic dopamine pathway are notable 
because this pathway is involved with the reward circuitry. 
It is possible that the mesolimbic dopamine neurons may be 
involved in the rewarding effects of ethanol. Alterations in 
the brain regions associated with this pathway may 
contribute to the reinforcing effects of ethanol. 
v 
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CHAPTER I 
INTRODUCTION 
Alcohol abuse and alcoholism represent serious health 
problems in the United States. Approximately 18 million 
adults exhibit some form of alcoholism, alcohol dependence, 
or alcohol abuse, and at least 3 out of 100 deaths in the 
United States can be attributed to alcohol use (Van Natta et 
al. 1984). 
Several central nervous system (CNS) neurotransmitter 
systems appear to be sensitive to alcohol administration. 
These include: the gamma-aminobutyric acid (GABA) system, 
the glutamate system, the dopamine system, the 
norepinephrine system, and the serotonin system (Greenberg 
et al. 1986; Valverius et al. 1987; Celetano et al. 1988; 
Murphy et al. 1988; Lovinger et al. 1989). Of particular 
interest is the dopaminergic system because both the 
nigrostriatal dopamine pathway, which is involved with 
locomotor activity (Fibiger et al. 1974; Liljequist et al. 
1981), and the mesolimbic dopamine pathway, which has been 
implicated in the reinforcement of several drugs of abuse 
(Lyness et al. 1979; Bozarth and Wise 1981; Matthews and 
German 1984), appear to be sensitive to the effects 
1 
2 
of ethanol exposure (Mereu et al. 1984; Gessa et al. 1985). 
In light of ethanol's reported actions on locomotor activity 
and its apparent reinforcing properties, it was hypothesized 
that chronic ethanol consumption either alters the ability 
of the dopamine signal to effect cellular changes through 
signal transduction or alters the level of dopamine itself. 
In order to test this hypothesis, I proposed to examine the 
effects of chronic ethanol consumption on the level of 
dopamine as well as several membrane components involved 
with signal transduction. This is important because of the 
substantial amount of evidence for ethanol's effects on CNS 
membranes and membrane components (Hoffman and Tabakof f 
1979; Rabin and Molinoff 1981; Sun and Sun 1985; Hruska 
1988).The membrane components which were examined include 
the 01 and 02 dopamine receptors, the stimulatory (s) and 
inhibitory (i) guanine nucleotide binding proteins 
(G proteins) which couple the dopamine receptors to 
adenylate cyclase, and the activity of dopamine-stimulated 
and dopamine-inhibited adenylate cyclase. These components 
were measured in brain regions which are associated either 
with the nigrostriatal system or mesolimbic dopamine system. 
Changes in the level of one or more of the membrane 
components (receptors, G proteins, or adenylate cyclase 
activity) could result in alterations in cellular activity. 
Changes in dopamine or in these membrane components could 
contribute to ethanol-induced changes in motor activity and 
3 
to the reinforcing effects of ethanol. 
CHAPTER II 
LITERATURE REVIEW 
The Dopaminergic System 
In the central nervous system, dopamine has been 
identified in several brain regions including the striatum, 
the nucleus accumbens, and the cortex (Hokfelt et al. 1976; 
Arliuson et al. 1984; Seguela et al. 1988). There are two 
major dopaminergic pathways: the nigrostriatal pathway and 
the mesolimbic dopamine pathway. The nigrostriatal pathway 
originates in the substantia nigra which sends projections 
to the striatum and collaterals to the globus pallidus 
(Fibiger et al. 1974; Lindvall and Bjorkland 1979). This 
pathway is a major component of the extrapyramidal motor 
system (Fibiger et al. 1974). The mesolimbic dopamine 
pathway consisting of projections from the ventral tegmental 
area to the nucleus accumbens (Lindvall et al. 1978; Nauta 
et al. 1978) is recognized as an important component of the 
reward circuitry (Phillips and Fibiger 1978). 
Dopamine, a catecholamine, is synthesized from its 
amino acid precursor tyrosine by the action of the enzymes 
tyrosine hydroxylase and aromatic amino acid decarboxylase 
Tyrosine is converted to 3,4-dihydroxyphenylalanine (DOPA) 
4 
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by the enzyme tyrosine hydroxylase. This enzyme is 
stereospecific and requires molecular oxygen (02}, ferrous 
ion (Fe+2), and the cofactor tetrahydropteridine. It serves 
as the rate limiting step in the biosynthesis of dopamine. 
The second enzyme involved in catecholamine synthesis is 
aromatic amino acid decarboxylase. This enzyme catalyzes the 
conversion of DOPA to dopamine. 
The major enzymes in metabolic degradation of the 
catecholamines are monoamine oxidase (MAO} and catechol-0-
methyltransferase (COMT). Monoamine oxidase converts 
catecholamines to their corresponding aldehydes. Dopamine is 
converted to 3,4-dihydroxyphenylacetaldehyde. This aldehyde 
intermediate is rapidly oxidized by the enzyme aldehyde 
dehydrogenase. The aldehyde, 
3,4-dihydroxyphenylacetaldehyde, is converted to 
3,4-dihydroxyphenylacetic acid (DOPAC) which in turn is 
converted to homovanillic acid (HVA) by the enzyme 
catechol-0-methyltransferase (Cooper et al. 1986). 
There are two types of dopamine receptors (Kebabian and 
Calne 1979}, originally defined by either an ability to 
stimulate adenylate cyclase activity (the Dl receptor) 
(Iversen 1975} or an inability to stimulate adenylate 
cyclase activity (the D2 receptor). In addition to the 
stimulation of adenylate cyclase, the Dl receptor may be 
coupled to inositol phosphate production and calcium (Ca+2} 
mobilization (Mahan et al. 1990). The 02 receptors are 
6 
characterized functionally by their ability to inhibit 
adenylate cyclase activity (Enjalbert and Bockaert 1983). 
The D2 receptor appears to couple selectively with the Gi2 
subtype (Jones and Reed 1987) of the G proteins (Senogles et 
al. 1990). Activation of 02 receptors also inhibits calcium 
channels, increases potassium conduction, and may inhibit 
accumulation of inositol phosphate (Simmonds and Strange 
1985; Malgaroli et al. 1987; Lacey et al. 1987). 
The Dl and 02 dopamine receptors exist in two forms: a 
high affinity state and a low affinity state with respect 
to agonists (Sibley et al. 1982; Leff et al. 1985). The 
state of these receptors is modulated by the guanine 
nucleotide binding proteins (G proteins) which couple the 
receptors to adenylate cyclase (Delean et al. 1982). The 
binding of an agonist to the receptor promotes a 
receptor-G protein interaction. The agonist is bound with 
higher affinity to the receptor of the resulting ternary 
complex (agonist-receptor-G protein) (Boeynaems and Dumont 
1975). When guanosine triphosphate (GTP) binds to this 
complex, the receptor dissociates from the G protein and is 
converted to the low affinity state. The GTP-G protein 
complex is the active intermediate which interacts with 
adenylate cyclase (Katada et al. 1984). 
In order to study the dopamine receptors, a variety of 
pharmacological ligands have been developed. Some examples 
of the Dl agonists include SKF 38393 and SKF 82526 (Setler 
7 
et al. 1978; Flaim et al. 1985). Examples of D2 agonists 
include LY 141865, RU 24213, and propylnorapomorphine (NPA) 
(Miller et al. 1976; Euvrard et al. 1980; Titus et al. 
1983). Dopamine antagonists have also been developed. These 
include the Dl antagonists SCH 23390 and SKF 83566 (Hyttel 
1983; O'Boyle and Waddington 1984) and the D2 antagonists 
spiperone, haloperidol, and YM 09151-2 (Hyttel 1978; Grewe 
et al. 1982). 
Antagonist binding exhibits different characteristics 
than agonist binding. Combined use of agonist and antagonist 
binding exhibits competition curves that can be resolved 
into the high affinity component and the low affinity 
component. Most agonists bind to a receptor population 
representing the high affinity component. In the presence of 
guanine nucleotides (i.e. GTP and 
5'-guanylylimidodiphosphate), agonist/antagonist curves 
represent a single affinity state similar to the low 
affinity component. Guanine nucleotides bind to the 
agonist-receptor-G protein complex resulting in the 
conversion of the receptor to its low affinity state. 
Agonist binding is decreased in the presence of guanine 
nucleotides, whereas antagonist binding which measures both 
the agonist high affinity component and the low affinity 
component is not altered. (Boeynaems and Dumont 1975; 
Jacobs and Cuatrecasas 1976; Limbird 1981; Hess and Creese 
1987). Antagonist and agonist binding assays can be used to 
8 
measure receptor conversion. 
several different functions have been associated with 
the dopamine Dl receptor; these functions may vary with the 
tissue localization of the receptor. The prototype Dl 
receptor is located in the parathyroid gland and mediates 
the release of parathyroid hormone (Niznik et al. 1988). 
Peripheral Dl receptors promote renal vasodilatory responses 
(Kohli and Goldberg 1987) and appear to modulate gap 
junction permeability in the retina (Lasater and Dowling 
1985). In the central nervous system, Dl receptors may exert 
a modulatory influence on the activity of the D2 receptor 
(Clark and White 1987). Presynaptic Dl receptors are located 
on GABAergic terminals in the substantia nigra, possibly 
regulating the release of GABA (Filloux et al. 1987). During 
development, central nervous system Dl receptor stimulation 
may be involved with regulation of neuron growth and 
differentiation (Lankford et al. 1988). 
The neuronal Dl receptor is a glycoprotein (Niznik et 
al. 1986). A polypeptide of apparent Mr=72,000/74,000 
represents the major ligand binding subunit (Niznik et al. 
1988). The polypeptide is sialylated and has terminal 
mannose residues. However, the neuronal receptor and the 
parathyroid receptor are differentially glycosylated. Upon 
complete deglycosylation, the Dl receptor (neuronal and 
parathyroid) is a single polypeptide Mr=46000. This 
polypeptide probably represents the protein backbone of 
central and peripheral Dl receptors (Jarvie et al. 1989; 
Niznik et al. 1989). 
9 
Recently, four laboratories cloned a cDNA encoding the 
Dl dopamine receptor coupled to the stimulation of adenylate 
cyclase (Dearry et al. 1990; Monsma et al. 1990; Sunahara et 
al. 1990; Zhou et al. 1990). A Dl clone was used to isolate 
and characterize the gene encoding the human Dl dopamine 
receptor. This gene is located on an intronless region of 
the long arm of chromosome 5 and encodes a protein of 446 
amino acids with a predicted molecular mass of 49,300. The 
protein sequence of this receptor indicates the presence of 
seven transmembrane segments which is characteristic of 
G protein-coupled receptors (Dixon et al. 1986; Kubo et al 
1986; Kobilka et al. 1987; Bonner et al. 1989). There are 
several potential sites for post-translational modification 
including a cysteine residue in the carboxy terminus that is 
conserved in most G protein-coupled receptors and two 
consensus sequences for cAMP-dependent protein kinase 
phosphorylation. The cloning of the gene for a Dl dopamine 
receptor will provide a valuable tool to study the 
regulation and function of this receptor. 
DARPP-32 (gopamine- and gdenosine 3 1 :5'-monophosphate-
~egulated RhosphoRrotein; molecular weight:32 kD) is a 
cytosolic protein enriched in dopaEinoceptive neurons of the 
brain (Hemmings and Greengard 1986). Its distribution 
correlates with the distribution of the 01 receptors 
10 
coupled to adenylate cyclase (Schalling et al. 1990). 
Dopamine increases the state of phosphorylation of OARPP-32. 
upon phosphorylation, OARPP-32 is converted to a very potent 
inhibitor of protein phosphatase-1 (Hemmings et al. 1984). 
Protein phosphatase-1 dephosphorylates phosphoproteins that 
are substrates for a variety of protein kinases. Thus, one 
mechanism by which dopamine may modulate the phosphorylation 
state of substrates is through the phosphorylation and 
activation of OARPP-32 (Hemmings et al. 1989). 
The 02 dopamine receptor is also associated with a 
variety of functions. The prototype 02 receptor is located 
in the anterior pituitary and inhibits prolactin release 
(Weiner and Gangong 1978). Dopamine somatodendritic 
autoreceptors appear to be of the 02 receptor subtype 
(Lehmann et al. 1983; Brown et al. 1985). 02 receptors are 
also localized to the terminals of the cholinergic 
interneurons of the striatum. Stimulation of these 02 
receptors leads to the decreased release of acetylcholine. 
(Joyce and Marshall 1985, 1987; Stoof et al. 1987). 
The 02 receptor is a glycoprotein and the major ligand 
binding subunit is a polypeptide (Mr=94,000). This subunit 
contains acetylglucosamine chains and terminal sialic acid 
(Grigoriadis et al. 1988). After complete deglycosylation, 
the binding subunit is a polypeptide (Mr=44,000). It is not 
known whether this subunit represents the functional 02 
receptor moiety (Jarvie et al. 1988). 
A full-length cONA clone of the rat 02 receptor has 
been isolated (Bunzow et al. 1988). This cDNA clone was 
used to clone a human genomic fragment (ThD2Gl) which 
contains the last coding exon of the D2 receptor gene. The 
human 02 receptor is encoded by a gene located at the 
q22-q23 junction of chromosome 11. The 02 gene locus 
contains a frequent two allele Tagl RFLP (restriction 
fragment length polymorphism) (Grandy et al. 1989). 
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Two transcripts exist for the D2 receptor which differ 
only by the presence of an 87-bp insert (Rao et al. 1990). 
The 02 receptor is thought to be an integral membrane 
protein of seven transmembrane spanning regions similar to 
other G protein-coupled receptors (Lefkowitz and Caron 
1988). The 87-nucleotide insert is within the region coding 
for the third cytoplasmic loop. It is suggested the two 
forms of the 02 receptor represent alternately spliced 
transcripts. This hypothesis is consistent with the evidence 
of intrans in the rat 02 receptor gene (Bunzow et al. 1988). 
O'Malley and colleagues (1990) suggest there must be at 
least two genes that produce 02 receptor subtypes designated 
D2A and 02B. The 02A gene contains 8 exons and spans at 
least 50 kb with exons 2-7 clustered in approximately 13 kb 
of the genome. The 02A gene undergoes alternate RNA 
processing within intron s, resulting in an insertion of 29 
amino acids to the predicted 415 amino acid sequence of the 
D2A protein. The authors suggest the presence of 
tissue-specific factors that control not only D2A gene 
transcription but also alternate splicing of the pre-mRNA. 
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The dopamine Dl and D2 receptor sites are 
differentially distributed throughout the brain. The 
localization of these dopamine sites has been examined 
utilizing receptor autoradiography and in situ hybridization 
techniques (Boyson et al. 1986; Charuchinda et al. 1987; 
Mansour et al. 1990). The Dl sites are located in the basal 
ganglia, cortical regions, amygdala, and hippocampus and 
high concentrations of D2 sites are confined primarily to 
the olfactory bulb, basal ganglia, and pituitary. Lesion 
studies have demonstrated that both receptor subtypes are 
localized on presynaptic and postsynaptic membranes 
(Porceddu et al. 1986; Joyce and Marshall 1987; Filloux et 
al. 1987, 1988). In most brain regions, the 01 receptors, 
found predominately in the low affinity state, are present 
in greater density than the D2 receptors, found 
predominately in the high affinity agonist state (Huff and 
Molinoff 1984; Boyson et al. 1986; Richfield et al. 1989). 
Guanine nucleotide-sensitive and -insensitive Dl and 02 
receptors have been identified in several brain regions (De 
Keyser et al. 1989). A regional heterogeneity based on this 
guanine nucleotide effect has been proposed. These unique 
distributions of the Dl and 02 receptors suggest complex 
interactions resulting in dopamine-mediated behaviors. 
A complex functional interaction exists between the 01 and 
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D2 receptors which is involved in the generation of some 
motor behaviors. The 01 receptor exerts its greatest 
behavioral effects when the D2 receptor is stimulated 
simultaneously. (Barone et al. 1986). Braun (1986) has 
suggested that 01 receptor activation provides a "tonic" 
background which allows the "phasic" component of the D2 
receptor to be effective. Stimulation of the 02 receptor can 
initiate motor behavior optimally when there is a specific 
level of 01 receptor activation. The Dl receptor may control 
the qualitative changes in D2 stimulated behaviors. 
Dopamine has two general classes of behavioral action: 
motor activation and reward-mediated learning (Beninger et 
al. 1989; Miller et al. 1990; Wickens 1990). Dopamine 
stimulates motor activity (Beninger 1983j Starr and Starr 
1986; Johansson et al. 1987) and dopamine antagonists 
prevent locomotor stimulation by dopamine agonists (Hoffman 
and Beninger 1985; Molloy and Waddington 1985). Dopamine 
agonists facilitate, while dopamine antagonists impair, the 
effects of reward on learning (Zarevics and Setler 1979; 
Gallistel and Karras 1984; Mazurki and Beninger 1986). 
The neuronal model for reward-mediated learning 
suggests this learning process consists of the selection 
and strengthening of specific synaptic connections (Miller 
et al. 1990; Wickens 1990). The paradigm for synaptic 
strengthening involves two sequential processes. First, 
there is the selection of synapses (possibly corticostriatal 
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synapses). These synapses would have been activated as a 
result of a specific stimuli. The synapse must be effective 
in firing a striatal neuron. When this has taken place, a 
temporary "state of readiness" is established and the 
synapses are eligible for modification. Second, if the 
behavior which follows the neuronal discharge has 
motivationally favorable consequences, reward pathways (i.e. 
the mesolimbic dopamine pathway) are activated and the 
efficacy of synaptic transmission is enhanced in synapses in 
the "state of readiness". Subsequent encounters with these 
stimuli result in easier activation of the neuron by these 
synapses (synaptic enhancement). 
This synaptic enhancement may occur in 
dopamine-mediated motor activation as well as 
reward-mediated learning. Dopamine acting on 02 receptors of 
the striatal cholinergic terminals exerts an inhibitory 
effect on acetylcholine release (Stoof et al. 1987). Lower 
levels of acetylcholine reduce membrane resistance and the 
excitatory postsynaptic potential {EPSP) amplitude (Dodt and 
Misgeld 1986). This effect may lead to an enhancement of 
the synapses. Dopamine acting on the Dl receptors located on 
striatal projection neurons (Ariano 1987) may bring about 
the enhancement of selected corticostriatal synapses. These 
dopamine effects may in turn link dopamine-mediated motor 
activation to reward-mediated learning (Wickens 1990). 
Modulation of motivational processes and organization 
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and initiation of goal-directed behaviors are associated 
with the ascending projections of the ventral tegmental area 
(Fibiger et al. 1987; Phillips et al. 1982,1987). One of the 
largest projections is to the nucleus accumbens. 
Approximately 90% of nucleus accumbens dopamine derives from 
this projection (Nauta et al. 1978). The nucleus accumbens 
is a major component of the ventral striatum which provides 
a ventral pathway by which the limbic system and prefrontal 
areas can influence the initiation of voluntary motor 
behaviors (Nauta 1986). The ventral pallidum receives a 
dopamine projection from the ventral tegmental area (Nauta 
et al. 1978). This projection may modulate information 
related to motor function (Depue and Iacono 1989). It is 
also well established that the ventral tegmental area 
dopamine pathway mediates reward, specifically the incentive 
type of reward that activates goal acquisition (Stein 1983; 
Bozarth 1987; Fibiger and Phillips 1987). It has been 
suggested that the nucleus accumbens may serve as an 
interface between the limbic and motor systems. Dopamine 
activity in the nucleus accumbens appears to modulate the 
flow of motivational information from the limbic system to 
the motor system; thereby contributing to the processes of 
locomotor activity initiation, incentive, and goal-directed 
behaviors (Oades and Halliday 1987i Taghzouti et al. 1985; 
Depue and Iacono 1989). 
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G proteins 
G proteins are membrane-associated heterotrimeric 
proteins composed of a, p, and T subunits. The a subunit has 
a guanine nucleotide binding site. In a nonactivated state, 
GDP is bound to the a subunit. A stimulated receptor 
activates the G protein by catalyzing the exchange of GDP 
for GTP which leads to the dissociation of the Pr subunits 
from the a subunit. The GTP-bound a subunit is free to 
regulate the activity of various enzymes and ion channels 
(Breitweiser and Szabo 1985; Cockroft and Gompert 1985; 
Pfaffinger et al. 1985; Yatani et al. 1987, 1988). 
Molecular cloning techniques have allowed the isolation 
and characterization of cDNA clones for several G protein 
subunits. Four a 1 subunits have been identified which appear 
to arise from alternate splicing Eechanisms (Bray et al. 
1986). Other a subunits (i.e. ail, ai2, ail, a0 , az, and a1) are 
products of unique genes (Lochrie et al. 1985; Medynski et 
al. 1985; Jones and Reed 1987; Itoh et al. 1988). 
The guanine nucleotide binding proteins (G proteins) 
serve as signal transducers linking neurotransmitter and 
hormone receptors to membrane bound effectors (Chang and 
Bourne 1987; Stiles 1989; Birnbaurner 1990) .The G8 protein 
is linked to the activation of adenylate cyclase and to 
calcium (ca+2) channels (Gilman 1987j Yatani et al. 1987). 
The ~ protein is linked to the inhibition of adenylate 
cyclase and the activation of potassium (K+) channels 
17 
(Yatani et al. 1988). The G0 protein is the most abundant G 
protein in the brain and may be involved in the regulation 
of calcium (ca+2) and potassium (K+) channels (Birnbaumer et 
al. 1987). The Gi protein is coupled to rod and cone opsins 
and to the regulation of cGMP phosphodiesterase (Medynski et 
al. 1985). 
The a subunit amino acid sequences are highly 
conserved. The greatest variability among the sequences 
occurs at the amino (NH2) and carboxyl (COOH) terminals 
(Strathman et al. 1989). The ai and a0 subunits are post-
translationally modified by the addition of myristic acid 
(Buss et al. 1987). In the proposed tertiary structure, the 
amino and carboxyl terminals are spatially close to each 
other and face the plasma membrane. The guanine nucleotide 
binding site is on the cytoplasmic face of the protein 
(Holbrook and Kim 1989). The amino terminus may regulate the 
interaction of the Pr subunit complex with the a subunit 
(Navon and Fung 1987). The carboxyl terminus may have a 
receptor contact site and regulate receptor binding and 
activation of the G protein (Deretic and Hanun 1987; Sullivan 
et al. 1987; Weiss et al. 1988). It is proposed that the 
proximity of the receptor binding domain (carboxyl terminus) 
and the Pr interaction site (amino terminus) would provide 
the structural basis for conformational changes within the 
subunits which induce guanine nucleotide exchange and 
subunit dissociation. 
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several P and T subunits have been identified and there 
is heterogeneity among these subunits (Gierschek et al. 
!985; Hildebrandt et al. 1985; Gao et al. 1987). This 
heterogeneity may account for altered a subunit regulation 
and specific receptor recognition. The T subunit of the Gt 
protein is particularly distinct and may account for this G 
protein being an extrinsic membrane protein whereas the 
other G proteins are intrinsic membrane proteins. It is 
hypothesized that the PT complex is required for the 
efficient interaction of the a subunit with the receptor and 
activation of the guanine nucleotide exchange. This complex 
may also serve to anchor the G protein to the membrane 
(Weiss et al. 1988). 
The primary sequence has been determined for many of 
the receptors which are coupled to G proteins (e.g. dopamine 
receptors, adrenergic receptors, serotonin receptors, and 
muscarinic receptors) (Dixon et al. 1986; Kubo et al. 1986; 
Kobilka et al. 1987; Bonner et al. 1989). These receptors 
are predicted to have a tertiary structure of seven membrane 
spanning regions, three cytoplasmic loops and the carboxyl 
terminus on the cytoplasmic side of the membrane. The 
receptor-G protein interaction occurs within the cytoplasmic 
domains. The amino acid sequences of cytoplasmic loops I-II 
and III-IV are conserved, but the sequence of cytoplasmic 
loop V-VI is highly variable (Dahlman et al. 1987). The V-VI 
loop may contain the recognition sites for G protein binding 
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(Strader et al. 1987; Kobilka et al. 1988). The third 
cytoplasmic loop and the carboxyl terminal may influence 
receptor selectivity and G protein activation (O'Dowd et al. 
1988) • 
Receptor activation of the G proteins is described as a 
catalytic exchange requiring the dissociation of GDP before 
the binding of GTP (Wessling-Resnick et al. 1987). The 
molecular interactions during activation are allosteric and 
display positive cooperation (Wessling-Resnick and Johnson 
1987). It is proposed that agonist binding to the receptor 
induces conformational changes which increase binding 
affinity and efficiency in the interaction with the G 
protein (Wessling-Resnick et al. 1987). 
Adenylate cyclase 
Adenylate cyclase is one of the membrane effectors 
regulated by the G proteins. This enzyme is an integral 
membrane protein which catalyzes the synthesis of adenosine 
3',S'-monophosphate (cAMP), a second messenger for many 
hormones and neurotransmitters (Johnson and Dhanasekaran 
1989; Birnbaumer 1990). There are two species of this 
enzyme, and a cDNA encoding one form has been cloned 
(Graziano and Gilman 1987). The primary amino acid sequence 
consists of 1134 residues which represent two alternating 
sets of hydrophobic and hydrophilic regions. A proposed 
model suggests each hydrophobic domain contains six 
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transmembrane segments (Krupinski et al. 1989). The overall 
topology of adenylate cyclase resembles structures of 
various membrane channels and transporters (Gilman 1989). 
Gilman (1989} has suggested that adenylate cyclase may be a 
multifunctional molecule, serving as both an enzyme of cAMP 
synthesis and a transporter that exports cAMP from the cell. 
In the nervous system, hoanones and neurotransmitters 
affect the cellular content of cAMP. The cAMP levels are 
determined by the rate of synthesis from ATP by adenylate 
cyclase and the rate of hydrolysis to 5'-AMP by 
phosphodiesterase (Nathanson and Greengard 1981). The 
effects of cAMP are mediated by its activation of 
cAMP-dependent protein kinases. These protein kinases 
consist of two regulatory subunits and two catalytic 
subunits. The binding of cAMP to the regulatory subunits 
leads to the dissociation of the complex and the activated 
catalytic subunits are free to phosphorylate cellular 
proteins. This phosphorylation usually occurs on serine 
residues of the substrate, resulting in alterations in 
cellular function (Spiegel et al. 1985; Gilman 1989). 
Ethanol Effects on Dopamine Metabolism 
In animal studies, acute administration of ethanol has 
a biphasic effect on neural function. Low doses of ethanol 
cause behavioral stimulation whereas higher doses cause 
sedation (Hunt 1981; Majchrowicz 1981; Engel and Liljequist 
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l983; Di Chiara and Imperato 1985). Some of these behavioral 
changes may be attributed to the effects of ethanol on 
dopamine metabolism. Low doses result in increased dopamine 
synthesis, utilization, and release (Carlsson and Lindquist 
1973; Darden and Hunt 1977; Fadda et al. 1980). However, at 
higher doses there is a decrease in dopamine utilization and 
release with a greater increase in synthesis (Carlsson and 
Lindquist 1973; Darden and Hunt 1977j Bacapoulous et al. 
1978; Fadda et al. 1980). After chronic treatment with 
ethanol, dopamine synthesis and release are reduced (Hunt 
and Majchrowicz 1983) and the dopaminergic neurons exhibit a 
hyposensitivity to haloperidol and apomorphine (Tabakoff and 
Hoffman 1978; Tabakoff et al. 1978; Black et al. 1980). 
The mesolimbic dopamine neurons which originate in the 
ventral tegmental area (VTA) and project to the nucleus 
accumbens (Lindvall et al. 1978) appear to be more sensitive 
to ethanol than those of the nigrostriatal pathway. Low 
doses of ethanol produced a dose-dependent increase in the 
firing rate of dopaminergic neurons in the VTA (Gessa et al. 
1985; Brodie et al. 1990). Higher doses (approximately 
5-f old) were required to produce comparable responses in the 
dopamine neurons of the substantia nigra (Mereu et al. 
1984). Doses of ethanol which enhanced dopamine release in 
the nucleus accumbens of freely moving rats did not modify 
dopamine release in the striatum (Imperato and Di Chiara 
1986; Di Chiara and Imperato 1988). 
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The mesolimbic dopamine neurons have been implicated in 
the mediation of the reinforcing properties of drugs of 
abuse such as cocaine (Lyness et al. 1979; Roberts and Koob 
1983), heroin (Bozarth and Wise 1981), and morphine 
(Matthews and German 1984). It is possible these neurons may 
be involved in mediating the rewarding effects of ethanol 
(Koob and Weiss 1990; Lewis and June 1990; McBride et al. 
1990; Samson et al. 1990). 
The voluntary intake of ethanol by laboratory animals 
and humans may be influenced by genetic factors which in 
turn may be manifested in differences in specific 
neurotransmitter systems {Goodwin 1979; Deitrich and 
McClearn 1981; Schuckit et al. 1985). Animal models 
exhibiting alcohol preferring behaviors have been 
established to study the genetic and biological basis for 
alcohol abuse {Crabbe et al. 1985,1987). Neurochemical 
differences have been found between alcohol-preferring (P) 
and alcohol-nonpreferring (NP) rats. The differences appear 
to be genetic because they exist even in animals never 
exposed to alcohol. The levels of dopamine and its 
metabolites are lower in the nucleus accumbens of 
alcohol-preferring rats as compared with alcohol-
nonpreferring rats. In contrast, the dopamine content in the 
striatum and frontal cortex were not significantly different 
in these animal lines {Murphy et al. 1987,1988; McBride et 
al. 1990. 
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~thanol Effects on the Dopamine Receptors 
When reviewing the literature related to the effects of 
alcohol on dopamine receptors, it is important to consider 
differences among each laboratory's experimental protocols. 
Ethanol dose, route of administration, duration of 
treatment, animal species, and assay conditions may account 
for discrepancies in results obtained from different 
laboratories. Furthermore, most earlier studies concentrated 
on ethanol's effect on the dopamine 02 receptor due to the 
unavailability of a specific dopamine Dl receptor ligand 
until recently and many of these studies were limited to the 
striatal receptors. 
Ethanol treatment appears to affect dopamine receptors. 
However, the effects seem to vary with brain region analyzed 
and duration of treatment. Nevertheless, some 
generalizations can be made. 1) Short term ethanol exposure 
(7 days or less) does not alter the number or affinity of 
dopamine receptors (Hoffman and Tabakoff 1979). 2) Various 
studies report an increase, decrease, and no change in Dl 
and 02 receptor number in the mesolimbic area, striatum, and 
cortex after long term exposure in mice and rats (two weeks 
to thirty-two weeks) (Lai et al. 1980, Muller et al. 1980, 
Lucchi et al. 1983, 1988; Hruska 1988j Syvalahti et al. 
1988; Hietala et al. 1990). 3) An ethanol-associated effect 
in one brain region may not be present in all brain regions. 
For example, Muller at al. (1980) reported a significant 
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decrease in 02 receptors in the mesolimbic area, while 
there was no difference in striatal 02 receptors after long 
term ethanol exposure. 4) Ethanol does not consistently 
alter the affinity of dopamine receptors. That is, the 
majority of studies report ethanol exposure has no effect on 
the affinity of 01 and 02 receptors (Lai et al. 1980; Muller 
et al. 1980; Hruska 1988; Lucchi et al. 1988; Syvalahti et 
al. 1988; Hietala et al. 1990). 
A portion of ethanol's effects may relate to its action 
as a nonspecific membrane perturbant, altering the physical 
properties of the lipid components of cell membranes which 
may lead to changes in optimal membrane fluidity (Chin and 
Goldstein 1977; Sun and Sun 1985), for protein function. 
Neural membranes become more fluid with acute ethanol 
intoxication (Chin and Goldstein 1977). After chronic 
ethanol exposure, the membranes are resistant to the 
fluidizing effects of ethanol (Lyon and Goldstein 1983). 
This response may serve as an adaptive mechanism to 
compensate for the fluidizing effects of ethanol. Changes in 
membrane cholesterol content may be part of this adaptive 
mechanism because cholesterol can maintain the order of 
membrane phospholipids by hindering their movement (Stockton 
and Smith 1976; Crews et al. 1983j ~eagle 1985). Changes in 
memebrane composition and fluidity may alter receptor-ligand 
interactions, receptor-effector coupling, and enzyme 
activity (Guerri and Grisola 1983; Yeagle 1985). 
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g_thanol Effects on Adenylate Cyclase and G proteins 
Guanine nucleotide binding proteins (G proteins) are 
important components in signal transduction, coupling 
hormone and neurotransmitter receptors to second messenger 
pathways (e.g. adenylate cyclase pathway, ion channels, 
phosphoinositide pathway) (Sternweis et al. 1981; Cockcroft 
1987; Codina et al. 1987; Hescheler et al. 1987). The 
G proteins are heterotrimers, consisting of a, p, and T 
subunits. The a subunit contains a guanine nucleotide 
binding site and displays GTPase activity (Northup et al. 
1983). 
In the adenylate cyclase system, an agonist interacts 
with a receptor resulting in the association of the 
agonist-receptor complex with the Gs protein which has GDP 
bound to the a subunit. This interaction promotes the 
displacement of GDP allowing the binding of GTP to the a 
subunit. When GTP binds, the agonist-receptor-G protein 
complex dissociates. The a subunit bound to GTP dissociates 
from the PT subunits of the G protein and in turn interacts 
with adenylate cyclase. The activation of adenylate cyclase 
by the a subunit is terminated by hydrolysis of GTP and 
reassociation of the a subunit with the ~r subunit (Gilman 
1987, 1989; Freissmuth et al. 1989; Johnson and Dhanasekaran 
1989). 
Protein-protein interactions within the cell membrane, 
such as those involving G proteins, may be susceptible to 
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the actions of ethanol. Under acute conditions, some studies 
have demonstrated a selective effect of ethanol on Gs, the 
stimulatory guanine nucleotide binding protein, rather than 
on the adenylate cyclase enzYllle or the receptor linked to 
the G protein. In studies with homogenates of mouse 
striatum, ethanol in vitro elicited an increase in basal 
adenylate cyclase activity. This effect was enhanced in the 
presence of dopamine and guanine nucleotides (Rabin and 
Molinoff 1981; Luthin and Tabakoff 1984). A similar effect 
was observed in cerebral cortex. Ethanol increased guanine 
nucleotide-stimulated and isoproterenol-stimulated adenylate 
cyclase activity {Saito et al. 1985). 
Studies of ethanol-adenylate cyclase interactions in 
cultured cells have supported the findings in brain membrane 
preparations. In several cultured cell lines, including the 
NlE-115, NG 108-15, and S49 1Y111phoma lines, acute ethanol 
exposure increased basal, and to a greater extent, 
agonist-stimulated, guanine nucleotide-stimulated, and 
fluoride-stimulated adenylate cyclase activity (Rabin and 
Molinoff 1983; Gordon et al. 1986). It has been postulated 
that acutely, ethanol appears to alter the rate of 
activation of Gs and to enhance the interaction of a 1 with 
guanine nucleotides (Rabin and Molinoff 1981, 1983; Luthin 
and Tabakoff 1984). 
Since ethanol increases the stiEulation of adenylate 
cyclase under acute conditions, it is possible that there 
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would be an adaptive change in adenylate cyclase activity 
after chronic ethanol exposure. Dopamine-stimulated 
adenylate cyclase activity is reduced after chronic ethanol 
treatment in striatal membranes of mice and rats (Tabakoff 
and Hoffman 1979; Lucchi et al. 1983; Saffey et al. 1988). 
In vitro addition of ethanol to striatal membranes restored 
dopamine-stimulated adenylate cyclase activity to normal 
levels, indicating that membranes from ethanol-tolerant rats 
require the presence of ethanol for normal activity 
(Tabakoff and Hoffman 1979). In contrast, another study 
reported an increase in dopamine-stimulated, 
GTP-stimulated, and sodium fluoride-stimulated adenylate 
cyclase activities in the striatum of chronically 
ethanol-treated rats (Rabin 1987). The discrepancies may be 
related to different strains of rat, mode and duration of 
ethanol administration, or time of assessment relative to 
ethanol withdrawal. 
Norepinephrine-stimulated adenylate cyclase activity in 
the cerebral cortex is affected by withdrawal from chronic 
ethanol exposure. During ethanol withdrawal, there was a 
decrease in this activity in the cerebral cortices of mice 
and rats {French et al. 1975; Saito et al. 1987}. Also, at 
the time of withdrawal, the stimulation of adenylate cyclase 
by guanine nucleotides, isoproterenol, vasoactive intestinal 
peptide, and forskolin was decreased (Saito et al. 1987). 
The effect of chronic ethanol exposure on adenylate 
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cyclase activity has also been examined in cultured cells. 
The neuroblastoma cell lines, NlE-115 and NG 108-15, 
displayed a decrease in the response of adenylate cyclase to 
prostaglandin El stimulation after chronic ethanol 
treatment. The addition of ethanol restored the response to 
control values (Richelson et al. 1986). Chronic ethanol 
treatment of primary cerebellar cultures resulted in a 
reduction in isoproterenol-stimulated and 
adenosine-stimulated adenylate cyclase activity (Rabin 
1990) . 
It has been hypothesized that changes in adenylate 
cyclase activity after chronic ethanol treatment are 
indicative of an uncoupled receptor-adenylate cyclase system 
(Hoffman and Tabakoff 1990). 
Alternatively, the changes in adenylate cyclase 
activity following chronic ethanol exposure may also 
reflect qualitative or quantitative changes in the a subunit 
of the Gs protein. Mochly-Rosen and colleagues (1988) 
demonstrated a decrease in :mRNA levels and protein content 
of the a subunit of the Gs protein after chronic ethanol 
treatment using the neuroblastoma cell line NG 108-15. 
Charness and colleagues (1988) also reported changes in G 
protein content in several ethanol-treated neuroblastoma 
cell lines. This group reported a decrease in the content of 
the Gs a subunit in the NG 108-15 and NlE-115 cell lines, 
but not in the N18TG2 cell line. They also found a 
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dose-dependent increase in the Gi a subunit in the NlE-115 
cell line, with no change in the NG108-15 and N18TG2 cell 
lines. Although the content of G proteins is altered in 
neural cell lines, no significant alteration in the content 
of the Gs a subunit was found in cerebral cortical tissue 
from chronically treated mice (Hoffman and Tabakoff 1990). 
Nonetheless, it has been suggested that in vivo chronic 
ethanol exposure may cause posttranslational modification of 
the a subunit which may alter its interaction with the 
receptor and adenylate cyclase (Hoffman and Tabakoff 1990). 
Possible Genetic Basis of Alcoholism 
The development of alcoholism may be determined by 
genetic as well as environmental factors (Tarter et al. 
1985; Zucker and Gomberg 1986; Cloninger 1987). Studies, 
particularly twin and adoption studies, have demonstrated 
there is a likely genetic predisposition to alcoholism 
(Cotton 1979; Cloninger et al. 1981; Hrubec and Omenn 1981; 
Kaprio et al. 1987). Several genes are probably involved in 
determining susceptibility to alcoholism. 
Two human studies suggest that alterations in platelet 
and lymphocyte adenylate cyclase may serve as markers for a 
genetic predisposition to alcoholism. 1) A reduction in the 
stimulation of adenylate cyclase activity by guanine 
nucleotides (36%), fluoride (26%), and prostaglandin El 
(35%) was observed in platelets from human alcoholic 
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patients (Tabakoff et al. 1988). Alcoholics with the 
greatest number of alcoholic first degree relatives had the 
largest reduction in stimulated adenylate cyclase activity. 
The reduced activity was also found in patients who had 
abstained for 1-4 years. It is possible the persistent 
reduction in platelet adenylate cyclase activity is an 
inherent characteristic of alcoholics (Tabakoff et al. 
1988). 2) Lower cAMP levels (a 75% decrease) were observed 
in lymphocytes obtained from alcoholic patients (Diamond et 
al. 1987). These cells were maintained in culture in the 
absence of alcohol for 4-6 generations. The differences in 
cAMP levels were still observed and these cells were more 
sensitive to ethanol's effects (Nagy et al. 1988). Thus, 
genetic factors may influence ethanol's effect on adenylate 
cyclase activity. 
Blum et al. (1990) recently reported an allelic 
association of the dopamine 02 receptor gene with 
alcoholism. In their patient population, the "Al" allele of 
the 02 receptor was found in 77% of the alcoholic patients 
and it was absent in 72% of the nonalcoholic patients. The 
authors suggest that an abnonaality in the gene coding for 
the 02 receptor may cause susceptibility to a subtype of 
alcoholism. The authors also suggest that the gene for the 
02 receptor may eventually be used as a diagnostic marker 
for the risk of alcoholism. In contrast to Blum's study of 
an association of the Al allele of the D2 receptor in 
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alcohol-related disease in humans, a study comparing 
alcohol-sensitive and alcohol-insensitive rat lines, Korpi 
et al. (1987) find no association of the striatal 
dopaminergic 02 receptors with sensitivity to alcohol. 
Although, Blum and colleagues (1990) have provided a 
candidate probe with potential promise in the research on 
the genetics of alcoholism, future genetic studies must 
include a broader living human sample as well as extended 
families of alcoholics. Furthermore, the classification of 
alcohol abusers should be done by a single, cooperative 
group, rather than by reviewing medical records of deceased 
patients. 
Proposed Studies 
Alcoholism and alcohol abuse constitute a major health 
problem in the United States. However, the biochemical 
mechanisms by which this disease manifest itself have not 
been fully investigated. Among the studies which have 
attempted to delineate these mechanisms are those which have 
demonstrated that several central nervous system 
neurotransmitters are sensitive to alcohol consumption 
(Greenberg et al. 1986; Valverius et al. 1987; Celetano et 
al. 1988; Murphy et al. 1988; Lovinger et al. 1989). Among 
the neurotransmitter systems which are sensitive to ethanol 
is the dopamine system. The dopaminergic system is involved 
with locomotor activity and is recognized as a component of 
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the reward circuitry (Fibiger et al. 1974; Phillips and 
Fibiger 1978). Since ethanol does have an effect on 
locomotor activity and displays reinforcing properties, it 
is hypothesized that chronic ethanol consumption may alter 
dopamine signal transduction or dopamine levels. It is the 
objective of the research described in this dissertation to 
specifically examine the biochemical changes in the 
dopaminergic system. 
This dissertation examined the effects of chronic 
ethanol exposure on several membrane components of the 
dopaminergic system, as well as the level of dopamine. The 
membrane components include the Dl and D2 receptors, the 
stimulatory and inhibitory guanine nucleotide binding 
proteins (G proteins), and adenylate cyclase activity. These 
components were measured in brain regions associated with 
the dopaminergic system. All studies were done on adult male 
Fisher 344 rats pair fed a control or 6.6% (v/v) ethanol 
liquid diet for one month prior to sacrifice at three months 
of age. This study is important because changes in dopamine 
levels or membrane components could result in alterations in 
cellular activity which could contribute to ethanol-induced 
changes in motor activity or to the reinforcing properties 
of ethanol. 
Animal Model 
CHAPTER III 
METHODS 
Male Fisher 344 rats (2 months) were used in these 
experiments. The animals were pair-fed using a 6.6% (v/v) 
ethanol liquid diet or control diet for 4-5 weeks (Noronha 
and Druse 1982). The caloric content of the control diet 
consisted of 21% protein, 29% fat 1 and 50% carbohydrate, the 
ethanol diet consisted of 21% protein, 29% fat, 15% 
carbohydrate, and 35% ethanol. Animals were maintained on a 
12:12 hour light/dark cycle. The animals were weighed weekly 
to ensure equal weight gain. 
Blood Ethanol Determination 
Blood ethanol levels were measured using an enzymatic 
kit {Sigma #330-1; St. Louis, MO). This kit accurately 
measures ethanol levels by measuring the nicotinamide 
adenine dinucleotide (NADH) formed when ethanol is converted 
to acetaldehyde via alcohol dehydrogenase (ADH) and reduced 
nicotinamide adenine dinucleotide (NAD) . An increase in 
absorbance at 340 nm occurs when HAD is converted to NADH. 
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ADH Ethanol + NAO ----------> Acetaldehyde + NADH 
The procedure required the deproteinization of blood 
samples by the addition of trichloroacetic acid (6.25%, 
w/v). The sample was allowed to stand at room temperature 
for 5 minutes, followed by a slow speed centrifugation 
(International Clinical Centrifuge, Model CL; International 
Equipment Co., Boston, MA) to obtain a clear supernatant. To 
each NAD-ADH assay vial, 2.9 ml glycine buffer (0.5 mol/L, 
pH 9.0) was added, and the vial was capped and inverted 
gently to dissolve contents. The sample (100 µl) was added 
to the vial, mixed by inversion, and incubated at 37°C for 
10 minutes. The sample was transferred to a cuvette and 
covered to exclude contamination and evaporation from air. 
The absorbance was recorded at 340 nm. Blood samples were 
collected at the time of sacrifice after an overnight fast. 
Dissection Technique 
The animals were decapitated between 7 a.m. and 10 
a.m •• The brains were quickly removed and dissected on a 
chilled glass plate. The frontal cortex, striatum, and 
nucleus accumbens were dissected. Other brain regions were 
dissected using the punch technique as described by 
Palkovits and Brownstein (1988). In the latter method brain 
samples were fixed to a specimen holder with the embedding 
medium Tissue-Tek (Miles; Elkart, IN). 
The mounted brains were sectioned using a cryostat set 
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at -15°C. Sections of 300-500 µm thickness were sliced and 
placed on ice-cold slides for punching. Punching tools with 
1.0 and 2.0 mm diameters were used to remove brain regions 
of interest. Punched areas included: globus pallidus, 
substantia nigra, ventral tegmental area, and ventral 
pallidum. Samples were stored at -80°C. All experiments were 
performed on frozen tissue. 
Dopamine Antagonist Binding Assay 
The dopamine (Dl and 02) binding sites in control and 
ethanol-treated animals were analyzed using a modified 
method of Hess and colleagues (1986). An antagonist binding 
assay measures total receptor number (high and low affinity 
state receptors). The 01 antagonist [3H]-SCH 23390 (New 
England Nuclear; Boston, MA) was used to measure total Dl 
sites and the 02 antagonist [ 3H)-spiperone (New England 
Nuclear; Boston, MA} was used to measure total D2 sites. 
Brain tissue was homogenized in 40 volumes of cold 
50 mM Tris-HCl buffer (pH 7.4) using a motorized teflon 
homogenizer (6 up and down strokes, setting 9) (Caframo 
RZR3; Warton, Ontario). The tissue was incubated for 15 
minutes at 37°C to remove endogenous dopamine, followed by 
centrifugation (SS34 rotor, Sorvall RC-SB centrifuge) at 
30,900 x g (16,000 rpm} for 20 minutes at 4°C. The pellet 
was resuspended in Tris-HCl buffer and centrifuged again as 
described above. This wash was repeated. The final pellet 
was suspended in assay buffer containing: 50 mM Tris-HCl, 
5 mM MgS04 , 0.5 mM EDTA, and 0.02% (w/v) ascorbic acid 
(pH 7.4). 
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The Dl binding assay was performed using a saturation-
competi tion assay containing 0.0-0.5 nM [ 3H]-SCH 23390 and 
o.o-5.0 nM SCH 23390. Nonspecific binding was determined by 
the dopamine antagonist, (+)-butaclamol. The 02 binding 
assay was performed using 0-1.0 nM [ 3H]-spiperone in the 
presence of 40 nM ketanserin to block serotonin sites (5-HT2 
sites). Nonspecific binding was determined using 1 µM 
(+)-butaclamol. 
The reaction was initiated with the addition of tissue 
homogenates (O.l to 0.3 mg protein/assay tube) (triplicate 
samples) and incubated for 30 minutes at 37°C. The reaction 
was terminated by vacuum filtration using a Brandel Cell 
Harvester (Gaithersburg, MD) with Whatman GF/C filters 
followed by three 5 milliliter (ml) washes with cold 
Tris-HCl buffer. Filters were placed in scintillation vials 
containing 10 ml Bio-Safe II (RPii Mt. Prospect, IL). The 
radioactivity on the filters was determined by liquid 
scintillation counting by the Beckman LS 7500 counter 
(Beckman, Fullerton, CA). 
The kinetic parameters (Kd and Bmax) were calculated by 
computer-assisted Scatchard analysis developed in this 
laboratory. The Scatchard plot is a linear transformation of 
the saturation isotherm. The x-axis is represented by bound 
values and the y-axis is represented by the bound/free 
values. From this plot, the Bmax (receptor number) is the 
x-intercept and the Kd (affinity) is -1/slope. 
Dopamine Agonist Binding Assay 
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The agonist binding assays were performed using a 
modification of the methods of Hess et al. (1986) and Sibley 
et al. (1982). Agonist binding was used to measure the 
percentage of receptors in the high affinity state and the 
ability of guanine nucleotides to convert the receptors from 
the high affinity state to the low affinity state. The 02 
receptors were measured using the 02 agonist, 
[ 3H]-N-n-propylnorapomorphine (NPA) (New England Nuclear; 
Boston, MA). The assay conditions were similar to that 
described previously for the antagonist binding assay, 
however, the assay buffer for the NPA studies also contained 
120 mM NaCl to stabilize the high affinity state. In order 
to measure the conversion of the D2 receptor from the high 
affinity state to the low affinity state, assays were 
performed in the absence and presence of 300 µM GTP. 
Adenylate Cyclase Assay 
Basal and dopamine-sensitive adenylate cyclase activity 
of brain regions obtained from control and ethanol-treated 
animals were assessed by a modification of the methods of 
Tabakoff and Hoffman (1979) and Battaglia et al. (1986). 
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Adenylate cyclase activity was measured in the striatum, 
nucleus accumbens, and frontal cortex. Samples were 
homogenized in 50 volumes of ice-cold homogenization buff er 
using a Tekmar Tissumizer (Cincinnati,OH) (setting 6, 10 
seconds). The homogenization buffer contained 10 mM 
Tris-maleate (pH 7.4) and 2.0 mM EGTA. The samples were 
centrifuged (SS34 rotor, Sorvall RC-SB centrifuge) at 
30,900 x g (16,000 rpm) for 10 minutes (4°C). The pellet was 
washed with homogenization buffer and centrifuged as 
described above. The final pellet was resuspended in the 
homogenization buffer. 
The assay buffer contained BO mM Tris-maleate (pH 7.4), 
0.4 mM EGTA, 4.0 mM MgS04 , 1.0 mM isobutylmethylxanthine 
(IBMX), 5.0 mM phosphocreatine, 0.02% (w/v) ascorbic acid, 
and 50 U/ml creatine kinase. Triplicate samples were 
preincubated in assay buffer for 5 minutes at 37°C in the 
presence (dopamine-stimulated/dopamine-inhibited) or absence 
(basal) of 100 µM dopamine. To measure Dl-stimulated 
adenylate cyclase activity, 50 nM spiperone was added to 
block 02 sites, while 100 nM SCH 23390 was used to block 01 
sites in assays of 02-inhibited adenylate cyclase activity. 
Basal adenylate cyclase activity was also measured in the 
presence of 100 µM forskolin, 10 mM NaF (sodium fluoride), 
or 100 µM GTP to determine the site of any ethanol effect. 
The reaction was initiated with the addition of 1 mM ATP 
(adenosine triphosphate) and allowed to proceed for 
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5 minutes at 37°C. The reaction was terminated by the 
addition of 50 nM sodium acetate buffer (pH 6.2) and 
iIIII1lersion in boiling water for 3 minutes. Precipitated 
protein was removed by centrifugation (SE12 rotor, Sorvall 
RC-SB centrifuge) at 21,800 x g (16,000 rpm) for 15 minutes 
(4°C). The supernatant was collected and stored at -80°C for 
measurement of cAMP levels by radioimmunoassay (RIA). 
cAMP Radioimmunoassay 
The cAMP radioimmunoassay was a modified method of 
steiner (1972). Samples and standards were acetylated to 
resemble the antigen used to generate the antibody for cAMP 
and to increase the sensitivity of the assay. Samples and 
standards were acetylated with the addition of triethylamine 
(20 µl) and acetic anhydride (10 µl). Duplicate acetylated 
standards (O to 500 fmoles of cAMP) and samples were 
transferred to 12 x 75 mm glass test tubes and [1llI]-cAMP 
(0.01 µCi) in 50 mM sodium acetate (pH 6.2) was added to 
each sample. The reaction was initiated with the addition of 
anti-cAMP antibody in sodium acetate buffer. The samples 
were incubated overnight (20°C). The assay was terminated 
with the addition of 1% (w/v) ga:mma globulin (50 µl) and 95% 
(v/v) isopropanol (2 ml). The samples were centrifuged for 
30 minutes at 1,623 x g (2800 rpm) in a Jouan GR4.11 
centrifuge (4°C). The supernatant was decanted and the 
radioactivity was measured by a LKB Wallac 1272 CliniGamma 
40 
gamma counter . 
~ransf ormation/Plasmid Preparation 
Lyophilized samples containing the cDNA probes for the 
a subunits of the G proteins (in the pGEM-2 plasmid) were 
obtained from Dr. Randall Reed (Jones and Reed 1987). The 
samples were diluted in Tris-EDTA buffer (10 mM Tris, 2.0 mM 
EDTA) and incubated for 5 minutes at 65°C. The samples were 
diluted again to a 1:20 dilution and used for 
transformation. 
The transformation procedure was the method of Chung et 
al. (1989). Microcentrifuge tubes were chilled on ice and 
100 µl of cells [E.coli HBlOl/F+;{F+=Tn lO:Kan recK) from 
Dr. Mark Kelley) and 1 µl of cDNA were added. Samples were 
mixed gently and incubated for 30 minutes at 4°C. After the 
incubation, LB broth (5 g NaCl, 10 g tryptone, 5 g yeast 
extract/lL) was added and the cells were incubated for 
30 minutes at 37°C. The cells were plated onto ampicillin 
plates and incubated at 37°C overnight. A single colony from 
the transformation plate was streaked onto a new ampicillin 
plate. The plate was incubated at 37°C overnight and served 
as the master plate. A single colony from the transformation 
plate was added to culture tubes containing LB broth and 
ampicillin. The cells were incubated at 37°C overnight. This 
preparation was used in the plasma preparation. 
The plasmid preparation (Morelle 1989) extracts the 
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plasmid DNA from the bacterial cells. The cells in the LB 
broth were aliquoted into microcentrifuge tubes and 
centrifuged for 1 minute at 10,000 x g (10,000 rpm) in a 
tabletop centrifuge (mc15, Hill Scientific, Derby, CT). The 
supernatant was removed by aspiration. The pellet was 
suspended in 250 µl of Tris-EDTA buffer (50 mM Tris, 100 mM 
EDTA) and 250 µl of NaOH/SDS buffer (200 mM NaOH, 1% (w/v) 
SDS) was added. After incubation for 5 minutes at room 
temperature, 250 µl of potassium acetate (2.55 M) buffer was 
added and the sample was centrifuged for 15 minutes at 4°C. 
The supernatant was transferred to another microcentrifuge 
tube and 400 µl of isopropanol (60%, v/v) was added. After 5 
minutes at room temperature, the sample was centrifuged for 
15 minutes at 10,000 x g (10,000 rpm) in a tabletop 
centrifuge (mc15; Hill Scientific). The supernatant was 
removed by aspiration and the pellet was washed with 
70% (v/v) ethanol by inversion. Following aspiration of 
ethanol, the pellet was incubated in a heat block (65°C) to 
evaporate the remaining ethanol. The pellet was suspended in 
Tris-EDTA (10 mM Tris, 1.0 mM EDTA) buffer. The cDNA probes 
were subjected to a DNA digest by Eco RI and separated on a 
0.7% (w/v) agarose gel to ensure purity. These samples of 
the cDNA probes for the G proteins were used for 
hybridization. 
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ENA Extraction and Analysis 
Total RNA was extracted from brain regions of control 
and ethanol-treated animals using the modified method of 
chomczynski and Sacchi (1987). The tissue was homogenized in 
guanidine isothiocyanate buffer (4.0 M guanidine 
isothiocyanate, 25 mM sodium citrate, 0.1 M 
2-mercaptoethanol, and 0.5% (w/v) sarcosyl) and allowed to 
stand for 5 minutes. The samples were transferred to 
microcentrifuge tubes. To these samples, 50 µl of 2 M sodium 
acetate (pH 4.0), 500 µl phenol, and 100 µl 
chloroform:isoamyl alcohol (49:1, v/v) were added. Samples 
were placed on ice for 15 minutes and then centrifuged for 
20 minutes at 10,000 x g (10,000 rpm) in a tabletop 
centrifuge (mc15, Hill Scientific). The aqueous layer was 
transferred to a new microcentrifuqe tube and an equal 
volume of isopropanol was added. The sample was then placed 
in a dry ice/methanol bath (-70DC) for one hour. The sample 
was centrifuged as described above. Following aspiration of 
isopropanol, the pellet was resuspended in guanidine 
isothiocyanate buffer. The sample was incubated in a heat 
block (65°C) for 5 minutes. To this sample, 10 µl 3.0 M 
sodium acetate (pH 5.2) and 100 µl isopropanol were added, 
prior to cooling on dry ice for 10 minutes. The sample was 
centrifuged as described and the supernatant was removed by 
aspiration. The pellet was washed with 70% (v/v) ethanol and 
centrifuged for 10 minutes at 10,000 x g (10,000 rpm) in a 
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tabletop centrifuge (mc15, Hill Scientific). The pellet was 
resuspended in diethyl pyrocarbonate (DEPC)-treated water 
and incubated in a heat block (65°C) for 5 minutes. Samples 
were stored at -20°c. The amount of RNA extracted was 
determined by a spectrophotometer (Spectronic 21D, Milton 
Roy co.) reading (260 nm). 
Equal amounts of RNA in DEPC-treated water were diluted 
to 1:10 and 1:1000 in microcentrifuge tubes. Formaldehyde 
(37%, v/v) in a 3.0 M sodium chloride/0.3 M sodium citrate 
(20X SSC) buffer (1:1) was added to each sample and the 
samples were incubated in a heat block (65°C) for 15 
minutes. The samples were loaded into the wells of the 
Manifold II with Nytran filter (0.45 µm) (Scheicher & 
Schuell; Keene, NH) and vacuum filtered. The wells were 
washed with lOX SSC buffer to remove the formaldehyde. The 
RNA was cross-linked to the Nytran using the UV Stratalinker 
(Stratagene; La Jolla, CA). 
Hybridization Procedure 
The levels of G protein mRNA from control and ethanol-
treated animals were measured using cDNA probes for the a 
subunits of the G proteins (Jones and Reed 1987). The Nytran 
filter was prehybridized for 2 hours under high stringency 
conditions in a buffer containing: 50% (v/v) formamide, lOOx 
Denhardt's solution [2% (w/v) polyvinylpyrrolide, 2% (w/v) 
bovine serum albumin, and 2% (w/v) Ficoll 400], 20% (v/v) 
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salmon sperm DNA (lOmg/ml), and a Na/P04 (5.0 M NaCl, 50 mM 
Na2po4 , and 0.5% (w/v) pyrophosphate) buffer. The cDNA probes 
isolated in the plasmid preparation were labeled with 
[32p]-CTP by random priming (Feinberg and Vogelstein 1983). 
The cDNA (2 µl) was diluted in 28 µl sterile distilled water 
and denatured at 100°C for 3 minutes. The sample was chilled 
on ice for 5 minutes. To the sample, 10 µl labeling buffer 
(250 mM Tris, 25 mM MgC12, 10 mM DTT, and 1 mM HEPES), 2 µl 
nonlabeling dNTP's (1.5 mM each ATP, GTP, TTP), 2 µl 
acetylated BSA (1 mg/ml), 1 µl Klenow (5 U), and 5 µl 
a-[ 32P]-dCTP were added and the sample was incubated at room 
temperature for one hour. The sample was heated to 100°c for 
2 minutes, chilled on ice, and 2 µl 0.5 M EDTA and 48 µl 
sterile distilled water were added. The sample was added to 
a Sephadex G50 column and centrifuged for 5 minutes at 
1000 x g (2000 rpm) (Beckman TJ-6 centrifuge). The 
32P-labeled cDNA was added to the prehybridization buffer and 
the filter was incubated overnight at 42°C on a rotator. 
After hybridization, the filter was washed three times 
(65°C) to remove excess labeled probe with a buffer 
containing 0.5% (v/v) sos and 0.2x SSC (high stringency). 
The filter was blotted dry and exposed on film at -ao0 c 
(Kodak XAR-5; Eastman Kodak Co., Rochester, N.Y.). The 
filters were stripped to remove all labeled probe. The 
stripping buffer contained 3.0 M sodium chloride, 0.2 M 
sodium phosphate, and 0.02 M EDTA (20X SSPE) and sos. The 
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filters were washed three times in boiling stripping buffer 
and exposed on film at -80°C. The filters were reprobed with 
cDNA probes for other G proteins and actin. Actin served as 
a control. 
western Analysis 
G protein content in control and ethanol-treated 
animals was measured by Western analysis. Tissue samples 
were homogenized in a TSA (0.01 M Tris (pH 8.0), 0.14 M 
NaCl, and 0.025% (w/v) NaN3 ) buffer containing: 0.5% (v/v) 
Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF), 5 
mM iodoacetamide, and 0.2 U/ml aprotinin. The samples were 
diluted 1:1 in a loading buffer (40 mM Tris, 4% (v/v) 
mercaptoethanol, 1% (w/v) SOS, 40% (v/v) glycerol, and 
Bromophenol Blue). The samples were boiled for 5 minutes 
and then centrifuged for 5 minutes in a tabletop centrifuge 
(mc15; Hill Scientific). The samples (20 µg protein) and 
molecular weight markers (Bio-Rad; Richmond, CA) were loaded 
onto a 10% (w/v) acrylamide gel (30% (w/v) acrylamide, 8% 
(w/v) N,N'-methylene-bisacrylamide, 4x Tris/SOS (pH 8.8), 
10% (v/v) ammonium persulfate, and TEMED) using the Bio-Rad 
Protein II gel apparatus (Laemmli 1970) . The gel was run at 
150 volts (constant voltage) in an electrophoresis buffer 
(0.125 M Tris base, 0.950 M glycine, and 0.05% (w/v) SDS). 
The proteins were either stained with Coomassie Blue (0.05% 
(w/v) Coomassie Blue, 20% (v/v) methanol, 10% (v/v) acetic 
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acid) or transferred to a nitrocellulose filter (0.2 µm) 
(Schleicher & Schuell; Keene, NH) by a Bio-Rad Mini 
Trans-Blot electrophoretic transfer cell. Prior to transfer, 
gels and nitrocellulose filters were equilibrated in 
transfer buffer (25 mM Tris base, 192 1llM glycine, 20% 
methanol) for 20 minutes. Protein transfer was completed by 
45 minutes at 150 mA (constant current). The filter was 
washed in TBST (100 mM Tris base, l.5M NaCl, and 5 ml Tween 
20) buffer for 5 minutes, followed by a one hour incubation 
in blot buffer (1% (v/v) TBST, 5% (w/v) powdered milk, 2 ml 
Nonidet P-40, 0.02% (w/v) SDS). After blot incubation, the 
primary antibody (anti-Ga8 or anti-Ga0 , Dupont; Boston, MA), 
diluted 1:1000 in blot buffer, was added to the filter and 
the filter was incubated overnight on a rotator at 4°C. The 
filter was washed three times for 15 minutes in TEST buffer. 
The second antibody ([ 1~I]-anti-rabbit IgG, Amersham; 
Arlington Heights,IL), diluted to 0.1 µCi/ml in blot buffer, 
was added to the filter and the filter was incubated for 
3 hours at room temperature on a rotator. The filter was 
washed three times for 15 minutes in TBST buffer. The filter 
was blotted dry and placed on film (Kodak XAR-5) and exposed 
at -80°C. Actin also served as the control in Western 
analysis. Actin monoclonal antibody (ICN; Costa Mesa, CA) 
was used as the primary antibody and ( 1~I]-anti-mouse IgG 
(ICN; Costa Mesa, CA) was used as the second antibody. 
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High Performance Liquid Chromatography 
Dopamine and DOPAC (3,4-dihydroxyphenylacetic acid) 
levels were measured in control and ethanol-treated animals 
by high performance liquid chromatography (HPLC) . Tissue 
samples were extracted in 0.1 M perchloric acid. The larger 
brain regions were homogenized by the Tekmar Tissumizer 
(setting 6, 10 seconds) (Tek.mar Co., Cinncinnati, OH). The 
other brain regions were homogenized by a motorized teflon 
homogenizer (Deltaware, Kimble Science Products) . The 
samples were centrifuged at 21,800 x g (16,000 rpm) for 20 
minutes at 4°C (SE12 rotor, Sorvall RC-SB centrifuge). 
Samples were separated by reverse phase HPLC using a C-18 
microbondapak column (3.9 mm x 30 cm) (Waters; Milford, MA). 
The mobile phase contained 0.1 M sodium phosphate-citric 
acid (pH 4.0), 1.0 mM disodium EDTA, 1 mM heptanesulfonic 
acid, and 7% (v/v) acetonitrile (Hortnagal et al. 1989). The 
internal standard 3,4-dihydroxybenzylamine (DHBA) was 
included in each sample. The flow rate was 0.7 ml/min and 
the sample run time was approximately 35 minutes. Six to 
eight individual samples were measured for each brain 
region. The HPLC system consisted of a Bio-Rad (Richmond,CA) 
pump, BAS (West Lafayette, IN) Amperometric detector LC-4B, 
and a Hewlett Packard (Avondale, PA) 3390A integrator. 
Synaptic Plasma Membrane Preparation 
Synaptic plasma membranes (SPM) were prepared from 
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whole brain from control and ethanol-treated animals by the 
method of Cotman and Matthews (i971). The preparation was 
maintained at 4°C. The brains were removed and homogenized 
(20%, w/v) in ice cold 0.32 M sucrose, 5.0 mM Tris (pH 7.0) 
buffer (sucrose buffer) using a motorized teflon homogenizer 
(Caframo RZR3; Warton, Ontario) (6 up and down strokes, 
setting 9). The homogenate was diluted to 10% (w/v) and 
centrifuged at 1100 x g (3000 rpm) for 5 minutes (SS34 
rotor, Sorvall RC-SB centrifuge). The supernatant was 
decanted into another centrifuge tube and pelleted at 
17,000 x g (13,700 rpm) for 10 minutes. The pellet was 
resuspended in sucrose buffer (10%, w/v) using a round 
bottom glass homogenizer and centrifuged for 20 minutes at 
11,000 x g (11,000 rpm). The pellet was suspended in 5 ml of 
sucrose buffer and layered onto a discontinuous 
Ficoll-sucrose gradient consisting of i3 ml of 
7.5% (w/v) Ficoll 400 in sucrose buffer and 13 ml of 13.0% 
Ficoll 400 in sucrose buffer. The gradient was centrifuged 
at 63,581 x g (22,000 rpm) for 45 minutes (SW-28 rotor, 
Beckman L8-M ultracentrifuge). The synaptosomal material, 
found at the 7.5% /13.0% Ficoll-sucrose interface, was 
removed and diluted with 4 voluDes of sucrose buffer, 
followed by centrifugation at 106,000 x g (24,000 rpm) for 
30 minutes. This synaptosomal pellet was suspended in a 
small volume of sucrose buffer, osmotically shocked in 6 
volumes of 6.0 mM Tris, pH 8.1 for i.5 hours, and 
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centrifuged for 15 minutes at 54,500 x g (20,000 rpm). The 
resulting pellet was resuspended in 5 ml of sucrose buffer 
and layered onto a discontinuous sucrose gradient consisting 
of the following concentrations in ascending order: 38.0% 
(w/v) (7.5 ml), 35.0% (w/v) (7.5 ml), 32.5% (w/v) (7.5 ml), 
and 25% (w/v) (7.5 ml}. This gradient was centrifuged for 
1.5 hours at 106,000 x g (24,250 rpm). The synaptic plasma 
membranes (SPM) were found at the 25% /32.5% interface. This 
layer was removed, diluted with 4 volumes of sucrose buffer, 
and centrifuged at 106,000 x g {24,250 rpm) for 30 minutes. 
The final pellet was suspended in sucrose buff er and stored 
at -80°C. Cholesterol and phospholipid content was measured 
in the SPM preparation. 
Phosphorus Assay 
The SPM lipids were extracted with chloroform:methanol 
(2:1, v/v) and dried under nitrogen (Felch et al. 1957) 
before measuring the phosphorus content by a modification of 
the method of Fiske and Subbarrow {1925). To each triplicate 
sample, 100 µl of perchloric acid (70%, v/v) was added. The 
samples were heated by a heat block to 170°C until 
colorless. After cooling, 1 ml of distilled water was added 
to each sample. Standards (0 to 40 µg phosphorus) were 
prepared from a stock solution of 1.3 mM KH2P04 (1 ml equals 
40 µg phosphorus). Perchloric acid (100 µl) and distilled 
water (1 ml} were also added to each standard. To each 
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sample and standard were added 250 µl of 2.5% (w/v) ammonium 
molybdate, 100 µl of reducer {3 g Na2S03 ·anhydrous, 60 g 
NaHS03 , and 1 g 1-amino-2-naphthol-4-sulphonic acid in 500 
ml distilled water), and distilled water (to a final volume 
of 2.5 ml). Samples and standards were allowed to stand at 
room temperature for 10 minutes. The 0.0. of the samples and 
standards was determined at 625 nm. 
Cholesterol Assay 
Cholesterol levels in the SPM preparations were assayed 
using the Sigma Diagnostic Kit (#351, st. Louis, MO). The 
Sigma procedure involves a series of enzymatic reactions 
coupled with the p-hydroxybenzenesulfonate and 
4-aminoantipyrine chromogenic system. In the last step of 
the reaction series, hydrogen peroxide reacts with 
4-aminoantipyrine and p-hydroxybenzenesulfonate in the 
presence of peroxidase to yield a quinoneimine dye, which 
has a maximum absorbance at 500 nm. 
The micro method (1 ml reaction volume) was used to 
measure total cholesterol in the synaptic plasma membrane 
(SPM) preparations from control and ethanol-treated animals. 
To each cuvette, 100 µl of SPM sample (in triplicate) and 
1 ml of cholesterol assay solution were added. The cuvettes 
were covered immediately and mixed by inversion. The 
cuvettes were incubated for 10 minutes at 37°C. The 
absorbance at 500 nm was recorded iI1llllediately after the 
incubation. Sample values were calculated based on the 
absorbance of the cholesterol standard (200 mg/dL). 
protein Determination 
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Protein levels were assayed following the method of 
Lowry et al. (1951). Human serum albumin (1 mg/ml) served as 
the protein standard. The standard curve consisted of 
concentrations of 0-50 µg protein. Standards and samples 
were incubated in 100 µl of 1.0 N NaOH for 30 minutes at 
room temperature to solubilize membrane bound proteins. To 
each sample and standard 1 ml of a solution (0.1:0.1:10, 
v/v/v) containing 1% (w/v) cupric sulfate, 2% (w/v) K+-Na+ 
tartrate, and 2% (w/v) sodium carbonate. After a 10 minute 
incubation, 100 µl of 1.0 N Falin phenol reagent was added. 
After a 30 minute incubation, the O.D. of the standards and 
samples was determined at 700 nm. 
Statistical Analysis 
The values reported for dopamine and DOPAC 
concentrations, adenylate cyclase activity, G protein 
content, and cholesterol and phospholipid levels represent 
the mean value ± the standard deviation of several samples. 
student's 't' test was used to determine statistical 
significance. P values of <0.05 represent significant 
differences. 
Certain types of experiments yield day to day 
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variability in control values. Nonetheless, a comparison of 
multiple studies of paired analyses of experimental and 
control animals may consistently show the same effect (e.g. 
an increase or decrease). To compensate for the day to day 
variability in control values, a pair of samples for control 
and ethanol-treated rats were assayed on the same day with 
the same assay conditions. Multiple paired samples were 
statistically analyzed utilizing the t-test for paired 
comparisons. This type of analysis was used for the dopamine 
Dl and 02 binding assays and for the slot blot analysis of 
G protein mRNA levels. 
chemicals 
Acetic anhydride 
Acrylamide 
Agarose 
1-Amino-2-napthol-4-sulphonic acid 
Ammonium molybdate 
Ammonium persulf ate 
Aprotinin 
Ascorbic acid 
ATP 
Anti-actin antibody 
Anti-cAMP antibody 
[ 125! J -anti mouse IgG 
[ 1251 J -anti rabbit IgG 
Blood ethanol kit 
Bio-Safe II 
Bovine serum albumin 
Bromophenol blue 
(+)-Butaclamol 
[ 125!] -cAMP 
Chloroform 
Cholesterol assay kit 
Citric acid 
Coomassie blue 
Cooper sulfate 
Creatine kinase 
Source 
Sigma 
BioRad 
IBI 
Sigma 
Mallinckrodt 
BioRad 
Sigma 
Mallinckrodt 
Sigma 
ICN 
RPI/BT! 
ICN 
Amersham 
Sigma 
RPI 
Siqma 
Sigma 
RBI 
BTI 
J.T. Baker 
Sigma 
Sigma 
Bio Rad 
Mallinckrodt 
Sigma 
53 
[32p]-CTP 
Dextran sulfate 
DHBA 
Diethyl pyrocarbonate 
Dithiothreitol 
DMSO 
DO PAC 
Dopamine 
EDTA 
EGTA 
Ethanol 
Ethidium bromide 
Ficoll 
Ficoll 400 
Formaldehyde 
Formamide 
Forskolin 
G protein antibodies 
'f-Globulin 
Glycerol 
Glycine 
GTP 
Guanine isothiocyante 
HEP ES 
1-Heptansulfonic acid 
Homovanillic acid 
Amer sham 
Sigma 
RBI 
Sigma 
Sigma 
Sigma 
RBI 
RBI 
Sigma 
Sigma 
Quantum 
IBI 
Sigma 
Pharmacia 
Sigma 
IBI/BRL 
Calbiochem 
Dupont 
Sigma 
Sigma 
Sigma 
Sigma 
IBI 
Sigma 
Sigma 
RBI 
54 
IBMX 
Iodoacetamide 
rsoamyl alcohol 
rsopropanol 
Ketanserin 
Kl en ow 
Magnesium chloride 
Magnesium sulfate 
Maleic acid 
2-Mercaptoethanol 
Methanol 
MOPS 
Nitrocellulose 
Nonfat dry milk 
Nonidet P-40 
Nytran 
Perchloric acid 
Phenol 
Phosphocreatine 
PMSF 
Polyvinylpyriolidine 
Potassium chloride 
Potassium phosphate 
[ 3H]-Propylnorapomorphine 
Sarkosyl 
Salmon sperm DNA 
Sigma 
Sigma 
Sigma 
Sigma 
Janssen 
IBI 
Sigma 
Mallinckrodt 
Sigma 
Sigma 
Baxter 
Sigma 
55 
Schleicher & Schuell 
carnation 
Sigma 
Schleicher & Schuell 
Mallinckrodt 
IBI 
Sigma 
Sigma 
Sigma 
Mallinckrodt 
Sigma 
New England Nuclear 
IBI 
Sigma 
SCH 23390 
[3H]-SCH 23390 
sephadex G-50 
sodium acetate 
sodium azide 
Sodium bisulf ate 
Sodium carbonate 
sodium chloride 
Sodium dodecyl sulfate 
Sodium fluoride 
Sodium hydroxide 
Sodium phosphate 
Sodium potassium tartrate 
Sodium sulfite 
Spiperone 
[3H]-Spiperone 
sucrose 
TEMED 
Tetrasodium pyrophosphate 
Triethylamine 
Tris 
Tris-HCL 
Triton X-100 
Trizma base 
Tryptone 
Tween-20 
56 
RBI 
New England Nuclear 
Sigma 
Mallinckrodt 
Sigma 
Sigma 
Sigma 
Sigma 
IBI 
Sigma 
J.T. Baker 
Sigma 
Mallinckrodt 
Mallinckrodt 
RBI 
New England Nuclear 
J.T. Baker 
BioRad 
Sigma 
Sigma 
BRL 
Sigma 
Sigma 
Sigma 
Difeo 
Sigma 
Whatman filters 
Yeast extract 
x-oMAT AR Diagnostic film 
Brandel 
Difeo 
Kodak 
57 
suppliers 
Amer sham 
J.T. Baker 
Baxter 
BioRad 
Brandel 
BRL 
BTI 
calbiochem 
carnation 
Dif co 
Dupont 
IBI 
ICN 
Janssen 
Kodak 
Mallinckrodt 
New England Nuclear 
Pharmacia 
Quantum 
RBI 
RPI 
Schleicher & Schuell 
Sigma 
Arlington Heights, IL. 
Jackson, TN. 
Muskegon, MI. 
Richmond, CA. 
Gaithersburg, MD. 
Gaithersburg, MD. 
Stoughton, MA. 
LaJolle, CA. 
Los Angeles, CA. 
Detroit, MI. 
Boston, MA. 
New Haven, CT. 
Costa Mesa, CA. 
Beerse, Belgium 
Rochester, NY. 
St. Louis, MO. 
Boston, MA. 
Pistcataway, NJ. 
Anaheim, CA. 
Natick, MA. 
Mount Prospect, IL. 
Keene, NH. 
St. Louis, MO. 
58 
Animal Model 
CHAPTER IV 
RESULTS 
This study examined Fisher 344 male rats that were 
pair-fed a control or ethanol liquid diet for 4-5 weeks 
(chronic exposure) prior to sacrifice at three months. The 
animals consumed 80-100 ml/day which corresponds to 20-25 g 
ethanol/kg weight for the ethanol-treated animals. The 
initial weights of the two-month old rats were 172.2 + 30.6 
grams for the control animals and 174.4 ± 31.0 grams for the 
ethanol-fed animals. After diet consumption for 4-5 weeks, 
the weights of the control animals were 238.1 ± 31.0 grams 
and the weights of the ethanol-treated animals were 233.8 + 
31.3 grams, reflecting comparable weight gain (Figure 1). 
The final weights were significantly greater than the 
initial weights (p<0.05). Blood ethanol levels of the 
ethanol-fed animals ranged between 80-130 mg/dL following a 
90 minute exposure to ethanol. Ethanol was undetectable in 
the control animals. 
Dopamine Dl Receptors 
The Dl receptors were assessed using the radioligand 
SCH 23390, a Dl antagonist which binds to both the high and 
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Figure 1. Weights of control and ethanol-treated animals. 
weights of control and ethanol-treated animals are shown. 
This data represents the mean weight + the standard 
deviation obtained from 130 ethanol-treated animals and 120 
control animals. The initial (two months of age) and final 
weights {12 to 13 weeks of age) of control and experimental 
animals were compared using Student's 't' test. There was no 
significant difference in the initial weights between 
control and ethanol-treated rats before diet consumption nor 
after 4-5 weeks of pair-feeding (p>0.05). 
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low affinity sites of the Dl receptor, in several brain 
regions of control and ethanol-treated animals. The regions 
analyzed include the frontal cortex, the striatum, the 
nucleus accumbens, and the globus pallidus. 
Typical binding assays for each brain region are 
depicted in Figures 2 to 5. The figures represent saturation 
curves. The x-axis represents ligand concentration (nM), 
while the y-axis indicates specific binding (pmol/mg 
protein). Scatchard plots are shown in the inset. In 
Scatchard plots, the x- and y-axes stand for bound and 
bound/free, respectively. Nonspecific binding of SCH 23390, 
determined in the presence of 1 uM (+)-butaclamol, accounted 
for 10-15% of the total bound radioactivity in the striatum 
and nucleus accumbens. Nonspecific binding was approximately 
25% in the globus pallidus and 25-30% in the frontal cortex. 
Under the assay conditions established in this laboratory, 
the Kd values ranged from 0.3 nM in the globus pallidus to 
2.0 nM in the frontal cortex. For a typical assay, an 
attempt was made to assess binding at ligand concentrations 
ranging from 1/8-1/10 Kd to 8-10 Kd. For the SCH 23390 
binding assays, several ligand concentrations between 0.05 
nM to 5.0 nM were selected. These concentrations were 
generally sufficient to establish saturation. In the frontal 
cortex, an apparent second site was detected at ligand 
concentrations greater than 6.0 nM. However, saturation was 
established at ligand concentrations of 4.0 to 5.5 nM. A 
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Figure 2. Binding of SCH 23390 to membranes from the nucleus 
accumbens of control and ethanol-treated animals. 
This figure represents a typical study of SCH 23390 binding 
to Dl receptors in membranes from the nucleus accumbens. The 
saturation curve depicts the binding of o.o nM to 0.5 nM 
[3H]-SCH 23390 and the binding of 0.5 nM [ 3H]-SCH 23390 in 
the presence of several concentrations (O.O nM to 5.0 nM) of 
unlabelled SCH 23390. Membranes from three control or 
ethanol-treated animals were pooled prior to analysis. The 
nonspecific binding, determined in the presence of 1 uM 
(+)-butaclamol, accounted for 10-15% of the total binding at 
each ligand concentration. The Kd and Bmax values ± the 
standard deviation, derived from the linear regression of 
the data points, were: 
Kd: 0.802 ± .088 nM (control) 
0.601 ± .055 nM (ethanol) 
Bmax: 0.788 ± .051 pmol/mg protein (control) 
0.476 ± .024 pmol/mg protein (ethanol) 
The differences in the Kd and Bmax values obtained from six 
similar paired experiments were statistically analyzed using 
the t-test for paired comparisons. It was found that the 
Bmax for Dl binding sites was significantly decreased 
(p<0.05) in the nucleus accumbens of ethanol-treated 
animals. There were no significant differences in the Kd 
values (p>0.05). 
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This figure represents a typical study of SCH 23390 binding 
to Dl receptors in membranes of the frontal cortex. The 
saturation curve depicts the binding of o.o nM to 0.5 nM 
[ 3H]-SCH 23390 and the binding of O. 5 nM [ 3HJ-SCH 23390 in 
the presence of several concentrations (O.O nM to 5.0 nM) of 
unlabelled SCH 23390. Membranes from three control or 
ethanol-treated animals were pooled prior to analysis. The 
nonspecific binding, determined in the presence of 1 µM 
(+)-butaclamol, accounted for 25-30% of the total binding at 
each ligand concentration. The Kd and Bmax values ± the 
standard deviation, derived from the linear regression of 
the data points, were: 
Kd: 2.422 ± .257 nM (control) 
2.282 ± .461 nM (ethanol) 
Bmax: 0.251 ± .017 pmollmg protein (control) 
0.209 ± .022 pmoltmg protein (ethanol) 
The differences in the Kd and Bmax values obtained from six 
similar paired experiments were statistically analyzed using 
the t-test for paired comparisons. It was found that the 
Bmax for Dl binding sites was significantly decreased 
(p<0.05) in the frontal cortex of ethanol-treated animals. 
There were no significant differences in the Kd values 
(p>0.05). 
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Figure 4. Binding of SCH 23390 to striatal membranes of 
control and ethanol-treated animals. 
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This figure represents a typical study of SCH 23390 binding 
to Dl receptors in striatal membranes. The saturation curve 
depicts the specific binding of o.o nM to 0.5 nM [3H]-SCH 
23390 and the binding of 0.5 nM [3H]-SCH 23390 in the 
presence of several concentrations (O.O nM to 5.0 nM) of 
unlabelled SCH 23390. Membranes from three control or 
ethanol-treated animals were pooled prior to analysis. The 
nonspecific binding, determined in the presence of 1 uM 
(+)-butaclamol, accounted for 10-15% of the total binding at 
each ligand concentration. The Kd and Bmax values ± the 
standard deviation, derived from the linear regression of 
the data points, were: 
Kd: 0.681 ± .029 nM (control) 
0.708 ± .025 nM (ethanol) 
Bmax: 0.420 ± .009 pmol/mg protein (control) 
0.398 ± .007 pmol/mg protein (ethanol) 
The differences in the Kd and Bmax values obtained from six 
similar paired experiments were statistically analyzed using 
the t-test for paired comparisons. It was found that neither 
the Kd nor the Bmax were significantly different in striatal 
membranes of ethanol-treated animals (p>0.05). 
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Figure 5. Binding of SCH 2339a to membranes from the globus 
pallidus of control and ethanol-treated animals. 
This figure represents a typical study of SCH 23390 binding 
to Dl receptors in membranes from the globus pallidus. The 
binding of SCH 23390 to membranes isolated from the globus 
pallidus was assayed in duplicate at each ligand 
concentration. The saturation curve depicts the binding of 
a.a nM to 1.a nM of [ 3H]-SCH 23390. Membranes from five 
control or ethanol-treated animals were pooled prior to 
analysis. The nonspecific binding, determined in the 
presence of 1 µM (+)-butaclamol, accounted for 25% of the 
total binding at each ligand concentration. The Kd and Bmax 
values ± the standard deviation, derived from the linear 
regression of the data points, were: 
Kd: 0.277 ± .048 nM (control) 
0.295 ± .043 nM (ethanol) 
Bmax: 0.306 ± .a2s pmol/mg protein (control) 
0.318 ± .a25 pmol/mg protein (ethanol) 
The differences in Kd and Bmax values obtained from four 
similar paired studies were statistically analyzed using the 
t-test for paired comparisons. It was found that neither the 
Kd nor the Bmax were significantly different in membranes of 
ethanol-treated animals (p>a.05). 
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component of SCH 23390 binding in the frontal cortex may be 
the serotonin (5-HT2) receptor (Hess et al. 1986). Binding 
assays for the frontal cortex were repeated in the presence 
of 40 nM ketanserin, a 5-HT2 antagonist, to discriminate 
multiple binding sites (Figure 6). For all binding assays, 
the Kd values were calculated from the slope and Bmax values 
from the x-intercept of the Scatchard plot utilizing linear 
regression. The linear fit of the Scatchard plots represent 
correlation coefficients of at least 0.9. 
Dopamine Dl binding sites were measured at multiple 
ligand concentrations when sufficient tissue was available. 
However, in quantitatively small regions, binding was 
initially examined using five three-point analyses. The 
three concentrations of [3H]-SCH 23390 represented 
approximately 1/5 Kd, Kd, and 5 Kd values. Four saturation 
analyses were performed to confirm the observations made 
using the three point analyses. The t-test for paired 
comparisons demonstrated that the Bmax was decreased 
approximately 40% in the nucleus accumbens and 25% in the 
frontal cortex (p<0.05). Figure 13 demonstrates that the 
ketanserin competition for [ 3H]-SCH 23390 binding in the 
frontal cortex represents a single binding site; therefore, 
the loss of Dl receptors in the frontal cortex appears to be 
only a loss of the Dl sites, not the serotonin sites. In 
contrast, there were no significant differences in either 
the Kd or Bmax for SCH 23390 binding to membranes from the 
Figure 6. Binding of SCH 23390 in the presence of 
ketanserin to cortical membranes from control 
and ethanol-treated rats. 
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This figure represents the binding of SCH 23390 in the 
presence of 40 nM ketanserin, a 5-HT2 antagonist, to the Dl 
receptors in membranes from the frontal cortex. The 
saturation curve depicts the binding of 0.0 nM to 0.5 nM 
[ 3H]-SCH 23390 and the binding of 0.5 nM [ 3H]-SCH 23390 in 
the presence of several concentrations (O.O nM to 5.0 nM) of 
unlabelled SCH 23390. The nonspecific binding, determined in 
the presence of 1 µM (+)-butaclamol, accounted for 35-40% of 
the total binding at each ligand concentration. The Kd and 
Bmax values ± the standard deviation, derived from the 
linear regression of the data points, were: 
Kd: 2.078 ± .140 nM (control) 
1.966 ± .164 nM (ethanol) 
Bmax: 0.216 ± .010 pmol/mg protein (control) 
0.175 ± .010 pmol/mg protein (ethanol) 
This experiment demonstrates that the ketanserin competition 
for SCH 23390 binding in the frontal cortex represents a 
single binding site. It was found that the Bmax for Dl 
binding sites in the presence of ketanserin was decreased 
(20%) in the frontal cortex of ethanol-treated animals, as 
observed in previous experiments. 
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striatum or globus pallidus of three-month old 
ethanol-treated rats (p>0.05). In addition, there was a 
nonsignif icant trend towards increased affinity (decreased 
Kd) in the nucleus accumbens in all experiments. Under the 
assay conditions described, binding sites for SCH 23390 were 
not detectable in the substantia nigra, ventral pallidum, 
and ventral tegmental area. Others have detected 01 sites in 
these areas utilizing quantitative autoradiography (Boyson 
et al. 1986; Mansour et al. 1990). 
This analysis has demonstrated that three-month old 
Fisher 344 rats, fed an ethanol liquid diet on a chronic 
basis, had a significant decrease in the Bmax for SCH 23390 
binding in the nucleus accumbens and frontal cortex 
(p<0.05). 
Dopamine D2 Binding Assay 
The radioligand [ 3H]-spiperone was used to measure 
total dopamine D2 sites in the striatum and nucleus 
accumbens of control and ethanol-treated animals. Figures 7 
and 8 represent typical binding assays in which 02 binding 
sites were measured in the striatum and nucleus accumbens, 
respectively. The D2 sites were labeled with [3H]-spiperone 
in the presence of 40 nM ketanserin to block 5-HT2 sites. 
Nonspecific binding, determined by 1 µM (+)-butaclamol, 
accounted for 15% to 35% of the total binding at the lowest 
to the highest concentration in the striatum and 25% to 40% 
Figure 7. Binding of spiperone to striatal membranes of 
control and ethanol-treated animals. 
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This figure represents a typical study of spiperone binding 
to 02 receptors in striatal membranes. The saturation curve 
depicts the binding of o.o nM to 0.9 nM [ 3H]-spiperone. 
Membranes from three control or ethanol-treated animals were 
pooled prior to analysis. The nonspecific binding, 
determined in the presence of 1 ~M (+)-butaclamol, 
represented 20% of the total binding. The Kd and Bmax values 
± the standard deviation, derived from the linear regression 
of the data points, were: 
Kd: 0.154 ± .012 nM (control) 
0.121 ± .014 nM (ethanol) 
Bmax: 0.248 ± .009 pmol/mg protein (control) 
0.252 ± .016 pmol/mg protein (ethanol) 
The differences in the Kd and Bmax values obtained from six 
similar paired experiments were statistically analyzed using 
the t-test for paired comparisons. It was found that neither 
the Kd nor the Bmax were significantly different in striatal 
membranes of three-month-old ethanol-treated animals 
{p>0.05). 
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Figure 8. Binding of spiperone to membranes from the 
nucleus accumbens of control and ethanol-treated 
animals. 
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This figure represents a typical study of spiperone binding 
to 02 receptors in membranes of the nucleus accumbens. The 
saturation curve depicts the binding of o.o nM to 0.8 nM 
[3H]-spiperone. Membranes from three control or 
ethanol-treated animals were pooled prior to analysis. The 
nonspecific binding, determined in the presence of 1 µM 
(+)-butaclamol, represented 30% of the total binding. The Kd 
and Bmax ± values the standard deviation, derived from the 
linear regression of the data points, were: 
Kd: 0.083 ± .012 nM (control) 
0.082 ± .006 nM (ethanol) 
Bmax: 0.129 ± .009 pmol/mg protein (control) 
0.112 ± .004 pmol/mg protein (ethanol) 
The differences in the Kd and Bmax values obtained from six 
similar paired experiments were statistically analyzed using 
the t-test for paired comparisons. It was found that neither 
the Kd nor the Bmax were significantly different in 
membranes from the nucleus accumbens of three-month-old 
ethanol-treated animals (p>0.05). 
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of that in the nucleus accumbens. The Kd values ranged 
from o.08 nM in the nucleus accumbens to 0.15 nM in the 
striatum. For the kinetic assays, several ligand 
concentrations between 0.0 nM and 1.0 nM were selected to 
establish saturation. The Kd values were calculated from the 
slope and Bmax values from the x-intercept of the Scatchard 
plots utilizing linear regression. The linear fit of the 
scatchard plots represent correlation coefficients of at 
least 0.9. 
The t-test for paired comparisons demonstrated there 
were no significant differences in either the Kd or Bmax for 
[ 3H]-spiperone binding to membranes from the striatum or the 
nucleus accumbens. This analysis indicates that neither the 
number nor the affinity of spiperone binding sites are 
altered in these brain regions of three-month-old Fisher 344 
rats fed an ethanol-containing liquid diet for one month 
prior to sacrifice. 
Using the binding techniques described, [3H]-spiperone 
labeled 02 receptors were below the level of detectability 
in the frontal cortex and globus pallidus. The nonspecific 
binding was at least 90% at ligand concentrations greater 
than 0.2 nM in these regions. As described for the Dl 
binding assay, three point surveys were also performed on 
quantitatively small regions. Spiperone binding sites were 
not measurable in the substantia nigra, ventral pallidum, 
and ventral tegmental area. 
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Dopamine 02 Agonist Binding Assay 
The dopamine receptors exist in two states: a high 
affinity state and a low affinity state. The radioligand 
propylnorapomorphine, a selective 02 agonist, was used to 
measure the high affinity state of the 02 receptor in brain 
regions of three-month-old control and ethanol-treated rats. 
The assay was also performed in the presence of GTP to 
measure the ability of these receptors to be converted to 
the low affinity state, which would indicate alterations in 
the functionality of the G proteins. The regions analyzed 
include the striatum and the nucleus accumbens, areas where 
spiperone binding was measurable using the described ligand 
binding technique. 
Both three point surveys and saturation assays were 
performed to assess [3H]-propylnorapomorphine binding and 
conversion of the 02 high affinity sites. In the three point 
assays, the concentrations of [ 3H]-propylnorapomorphine 
represented approximately 1/5 Kd, Kd, and 5 Kd values. 
Typical binding assays for each brain region are depicted in 
Figures 9 and 10. Binding assays reflecting conversion of 
the high affinity state to the low affinity state are shown 
in Figures 11 and 12. The figures represent saturation 
curves and Scatchard plots. Nonspecific binding, determined 
in the presence of 1 µM (+)-butaclamol, accounted for 
approximately 20% of the total radioactivity at the lowest 
ligand concentration and 50 % of the total radioactivity at 
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Figure 9. Binding of propylnorapomorphine to striatal 
membranes of control and ethanol-treated animals. 
The binding of [ 3H]-propylnorapomorphine to striatal 
membranes was assayed in duplicate at each ligand 
concentration. The saturation curve depicts the binding of 
o.o nM to 1.6 nM [3H]-propylnorapomorphine. Membranes from 
four control or ethanol-treated animals were pooled prior to 
analysis. The nonspecific binding, determined in the 
presence of 1 µM (+)-butaclamol, ranged from 20% to 50% of 
the total binding. The Kd and Bmax values ± the standard 
deviation, derived from the linear regression of the data 
points, were: 
Kd: 0.167 ± .030 nM (control) 
0.164 ± .024 nM (ethanol) 
Bmax: 0.208 ± .014 pmol/mg protein (control) 
0.201 ± .010 pmol/mg protein (ethanol) 
The differences in the Kd and Bmax values obtained from four 
similar paired experiments were statistically analyzed using 
the t-test for paired comparisons. It was found that 
neither the Kd nor the Bmax were significantly different in 
striatal membranes from three-month-old ethanol-treated 
Fisher 344 rats (p>0.05). 
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Figure 10. Binding of propylnorapomorphine to membranes from 
the nucleus accumbens of control and 
ethanol-treated rats. 
The binding of [3H]-propylnorapomorphine to membranes from 
the nucleus accumbens was assayed in duplicate at each 
ligand concentration. The saturation curve depicts the 
binding of o.o nM to 1.7 nM [3H]-propylnorapomorphine. 
Membranes from four control or ethanol-treated animals were 
pooled prior to analysis. The nonspecific binding, 
determined in the presence of 1 µM (+)-butaclamol, ranged 
from 20% to 50% of the total binding. The Kd and Bmax values 
± the standard deviation, derived from the linear regression 
of the data points, were: 
Kd: 0.373 ± .052 nM (control) 
0.494 ± .090 nM (ethanol) 
Bmax: 0.103 ± .008 pmol/mg protein (control) 
0.109 ± .012 pmol/mg protein (ethanol) 
The differences in the Kd and Bmax values obtained from four 
paired similar experiments were statistically analyzed using 
the t-test for paired comparisons. It was found that neither 
the Kd nor the Bmax were significantly different in 
membranes from the nucleus accumbens ethanol-treated Fisher 
344 rats (p>0.05). 
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of GTP to striatal membranes in control and 
ethanol-treated rats. 
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Figures a and b represent the conversion of the high 
affinity state of the 02 receptor to its low affinity state 
in ethanol-treated and control animals, respectively. The 
saturation curves depict the binding of 0.05 nM to 1.6 nM 
[ 3H]-propylnorapomorphine in the absence and presence of 
300 µM GTP. The Kd and Bmax values ± the standard deviation, 
derived from the linear regression of the data points, were: 
Ethanol-treated: Kd: 0.164 ± .024 nM 
Control: 
0.234 ± .044 nm (300 µM GTP) 
Bmax: 0.201 ± .010 pmol/mg protein 
0.111 ± .008 prnol/mg protein (300 µM GTP) 
Kd: 0.167 ± .030 nM 
0.244 ± .019 nM (300 µM GTP) 
Bmax: 0.208 ± .014 prnol/rng protein 
0.111 ± .004 pmol/rng protein (300 µM GTP) 
In the ethanol-treated animals approximately 45% of the 02 
high affinity sites were converted to the low affinity state 
and in the control animals, approximately 47% of the sites 
were converted. It was found that the proportion of 
striatal 02 sites converted from high affinity state to the 
low affinity state was not significantly altered by ethanol 
treatment (p>0.05). 
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Figure a and b represent the conversion of the high affinity 
state of the D2 receptor to the low affinity state in 
ethanol-treated and control animals, respectively. The 
saturation curves depict the binding of o.o nM to 1.7 nM 
[ 3HJ-propylnorapomorphine in the absence and presence of 
300 µM GTP. The Kd and Bmax values ± the standard deviation, 
derived from the linear regression of the data points, were: 
Ethanol-treated: Kd: 0.494 ± .090 nM 
Control: 
0.813 ± .123 nm (300 µM GTP) 
Bmax: 0.109 ± .012 pmol/mg protein 
0.075 ± .008 pmol/mg protein (300 µM GTP} 
Kd: 0.373 ± .052 nM 
0.735 ± .125 nM (300 µM GTP) 
Bmax: 0.103 ± .008 pmol/mg protein 
0.066 ± .007 pmol/mg protein (300 µM GTP) 
In the ethanol-treated animals approximately 31% of the D2 
high affinity sites were converted to the low affinity state 
and in the control animals, approximately 36% of the sites 
were converted. It was found that the proportion of the D2 
sites converted from the high affinity state to the low 
affinity state in the nucleus accumbens was not 
significantly altered by ethanol treatment (p>0.05). 
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the highest ligand concentration in the striatum and the 
nucleus accumbens. The Kd values ranged from 0.15 nM in the 
striatum to 0.40 nM in the nucleus accumbens; with the 
addition of GTP, there was approximately a two-fold increase 
in the Kd values. Several ligand concentrations between 
0.02 nM to 2.0 nM were selected to establish saturation. 
The Kd and Bmax values were calculated from the Scatchard 
plots utilizing linear regression analysis. The linear fit 
of the Scatchard plots represent correlation coefficients of 
at least 0.9. 
In membranes from both control and ethanol-fed rats, 
300 µM GTP stimulated the conversion of the high affinity 
binding state to the low affinity state. In the striatum, an 
average 50% of the high affinity sites were converted to the 
low affinity state, while in the nucleus accumbens, an 
average 35% of the high affinity sites were converted to the 
low affinity state. 
The t-test for paired comparisons demonstrated that 
there were no significant differences in either the Kd or 
Bmax for propylnorapomorphine binding to membranes from the 
striatum or nucleus accumbens (p>0.05). In addition, in the 
presence of GTP, the conversion of the high affinity state 
to the low affinity state was similar in membranes from 
control and ethanol-treated animals (p>0.05). The percent 
conversion for all experiments was statistically analyzed by 
Student's 't' test. The results of these studies demonstrate 
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that consumption of an ethanol-containing diet for one month 
does not alter the high affinity state of the D2 site or the 
ability of this site to convert to the low affinity state in 
three-month-old Fisher 344 rats. 
Determination of Dopamine and DOPAC Concentrations 
This study determined dopamine and 
3,4-dihydroxyphenylacetic acid (DOPAC) concentrations (ng/mg 
protein) in several brain regions of control and 
ethanol-treated animals. The regions analyzed include: the 
striatum, globus pallidus, and substantia nigra which are 
components of the nigrostriatal pathway and the nucleus 
accumbens, ventral pallidum, frontal cortex, and ventral 
tegmentum which are components of the mesolimbic dopamine 
pathway. The results of these studies, presented as the mean 
± the standard deviation, were compared for statistical 
significance using Student's 't' test • 
The results of these studies are depicted in Figures 13 
to 16. Six to eight individual samples from control rats and 
six to eight samples from ethanol-treated rats were examined 
for each brain region. In comparison to control animals, 
there was a 2- to 3-fold increase in dopamine and DOPAC 
concentrations in the frontal cortex, ventral tegmentum, and 
ventral pallidum, a 2-fold increase in DOPAC concentration 
in the substantia nigra (p<0.01), and approximately a 30% 
decrease in dopamine concentration in the substantia nigra 
Figure 13. Concentration of dopamine and DOPAC in the 
frontal cortex and nucleus accumbens. 
Figure a depicts the concentration (ng/mg protein) of 
dopamine and DOPAC in the frontal cortex. 
Dopamine 
DOPAC 
Ethanol 
5.33 ± 1.87 .. 
4.14 ± i.oa· 
Control 
2.23 ± 1.16 
2.61 ± 1.01 
Figure b depicts the concentration (ng/mg protein) of 
dopamine and DOPAC in the nucleus accumbens. 
Ethanol Control 
91 
Dopamine 180.3 ± 49.1 194.3 ± 45.6 
DOPAC 95.6 ± s1.s· 233.5 ± 94.3 
Each value represents the mean ± the standard deviation of 
values obtained from six to eight individual animals. The 
symbols • and •• indicate that values from control and 
ethanol-treated animals differ significantly at p<0.05 and 
p<0.01, respectively. 
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Figure 14. Concentration of dopamine and DOPAC in the 
ventral pallidum and the ventral tegmental area. 
Figure a depicts the concentration (ng/mg protein) of 
dopamine and DOPAC in the ventral pallidum. 
Dopamine 
DO PAC 
Ethanol 
31.5 ± io.a·· 
55.5 ± 35_5• 
Control 
14.0 ± 7.9 
17.9 ± 12.9 
Figure b depicts the concentration (ng/mg protein) of 
dopamine and DOPAC in the ventral tegmental area. 
Ethanol Control 
Dopamine 50.3 ± 11.a- 19.1 ± 5.8 
DOPAC 164.8 ± 60.a·· 77.2 ± 16.9 
Each value represents the mean ± the standard deviation of 
values obtained from six to eight individual animals. The 
symbols • and •• indicate that values from control and 
ethanol-treated animals differ significantly at p<0.05 and 
p<0.01, respectively. 
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Figure 15. Concentration of dopamine and DOPAC in the 
striatum and the globus pallidus. 
Figure a depicts the concentration (ng/mg protein) of 
dopamine and DOPAC in the striatum. 
Ethanol Control 
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Dopamine 
DOPAC 
265.5 ± 137.6 
87.4 ± 51.0 
278.4 ± 77.2 
125.7 ± 51.2 
Figure b depicts the concentration (ng/mg protein) of 
dopamine and DOPAC in the globus pallidus. 
Dopamine 
DOPAC 
Ethanol 
347.8 ± 96.2 
37.3 ± 8.7 
Control 
241.9 ± 88.8 
31.4 ± 11.8 
Each value represents the mean ± the standard deviation of 
values obtained from six to eight individual animals. The 
symbols • and •• indicate that values from control and 
ethanol-treated animals differ significantly at p<0.05 and 
p<0.01, respectively. 
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Figure 16. Concentration (ng/mg protein) of dopamine and 
DOPAC in the substantia nigra. 
Dopamine 
DOPAC 
Ethanol 
26.6 ± 4,9• 
21.2 ± 9,2·· 
Control 
38.6 ± 9.7 
8.2 ± 1.7 
Each value represents the mean ± the standard deviation of 
values obtained from six to eight individual animals. The 
symbols • and •• indicate that values from control and 
ethanol-treated animals differ significantly at p<0.05 and 
p<0.01, respectively. 
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(p<0.05). Although DOPAC was 60% below control values in 
the nucleus accumbens (p<0.01), the dopamine 
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concentration was not significantly altered (p>0.05). In the 
striatum and globus pallidus, dopamine and DOPAC 
concentrations were not significantly different (p>0.05). 
The findings of this study demonstrate that consumption of 
an ethanol liquid diet for one month results in significant 
changes in the concentration of dopamine and DOPAC in 
specific brain areas of three-month-old Fisher 344 rats. 
Adenylate Cyclase Activity 
Basal and dopamine-sensitive adenylate cyclase activity 
were measured in several brain regions of control and 
ethanol-treated animals. The brain regions analyzed include 
the striatum, nucleus accumbens, and frontal cortex. 
Adenylate cyclase activity also was assessed in the presence 
of forskolin, GTP, and sodium fluoride in order to identify 
the site of any observed change. Forskolin directly 
activates adenylate cyclase whereas GTP and sodium fluoride 
directly stimulate the G protein. The levels of cAMP 
(nmoles/mg protein/5 min) measured by radioi11UI1unoassay were 
used as an assessment of adenylate cyclase activity. 
Table 1 demonstrates the stiEulation or inhibition of 
adenylate cyclase by these drugs. There was a significant 
increase in adenylate cyclase activity in the presence of 
forskolin, GTP, and sodium fluoride in all brain regions 
Basal 
+ Forskolin 
+ NaF 
+ GTP 
Dopamine 
-stimulated 
-inhibited 
Table 1 
Adenylate Cyclase Activity 
(nmoles c'AMP/mg protein) 
Stria tum Accumbens 
0.14 + .03 0.08 ± .01 
42.5 ± 1. 3•• 27.0 ± 1. 4 •• 
4.46 ± . 4 3•• 2.24 ± • 3g•• 
1.12 ± .05 .. 0.63 ± . 21·· 
1.94 ± .23° 1.19 ± ,27• 
0. 92 ± • 09° ND 
100 
Cortex 
0.16 + .02 
6.72 ± . 25 .. 
2.05 ± • 33•• 
0.88 ± . 05•• 
1.01 ± .os· 
ND 
Each value represents the mean ± the standard deviation of 
three individual experiments for each brain region. Basal 
adenylate cyclase activity was measured in the absence or 
presence of either 100 µM forskolin, 100 µM GTP, or 10 mM 
NaF. The data also depicts the mean ± the standard deviation 
of three individual experiments of the stimulation (+ 50 nM 
spiperone) or inhibition (100 nM SCH 23390) of adenylate 
cyclase activity by 100 µM dopamine. The symbols • and •• 
indicate the values that differ siqnificantly at p<0.05 and 
p<0.01, respectively, as compared to basal values or basal 
values in the presence of GTP. 
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analyzed (p<0.01). Compared to basal adenylate cyclase 
activity in the presence of GTP, there was a significant 
increase in dopamine-stimulated adenylate cyclase activity 
(in the presence of 50 nM spiperone) in all regions and a 
significant decrease in dopamine-inhibited adenylate cyclase 
activity (in the presence of 100 nM SCH 23390) in the 
striatum (p<0.05). These results indicate that there was a 
true stimulation of the Dl receptors in the striatum, 
nucleus accumbens, and frontal cortex, and a true inhibition 
of the D2 receptors in the striatum. 
The results of this study are depicted in Figures 17 to 
19. Figure 17 represents the basal and dopamine-sensitive 
adenylate cyclase activity in the striatum and the effects 
of forskolin, GTP, and sodium fluoride on striatal adenylate 
cyclase activity. Similarly, Figures 18 and 19 depict the 
adenylate cyclase activity of the nucleus accumbens and the 
frontal cortex, respectively. The activity is defined as 
nmoles cAMP formed per mg protein per 5 minutes. The 
nonspecific binding determined by bovine serum albumin (BSA) 
was an average 3% of total binding and the cAMP antibody 
accounted for an average 30% of the total binding. Each 
value represents the mean ± the standard deviation of three 
individual experiments. Student's 't' test was used to 
determine significant differences. 
The results of this study of adenylate cyclase activity 
demonstrate that consumption of an ethanol liquid diet for 
Figure 17. The effect of chronic ethanol treatment on 
adenylate cyclase activity in the striatum of 
three-month-old rats. 
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Figures 17a, 17b, 17c, and 17d depict striatal basal 
adenylate cyclase activity in the absence of stimulatory 
chemicals (a), or in the presence of 100 µM GTP (b), 100 µM 
forskolin (c), or 10 nM sodium fluoride (NaF) (d). Figure 
17b also depicts 01-stimulated and D2-inhibited adenylate 
cyclase activity in the presence of GTP. The activity is 
defined as nmoles cAMP/mg protein. 
Each value represents the mean ± the standard deviation of 
three individual experiments. The symbols • and .. indicate 
that values from control and ethanol-treated animals differ 
significantly at p<0.05 and p<0.01, respectively. 
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Figure 18. The effect of chronic ethanol treatment on 
adenylate cyclase activity in the nucleus 
accumbens of three-month-old rats. 
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Figures 18a, lSb, 18c, and 18d depict basal adenylate 
cyclase activity of the nucleus accumbens in the absence of 
stimulatory chemicals (a), or in the presence of 
100 µM GTP (b), 100 µM forskolin (c), or 10 nM sodium 
fluoride (NaF) (d). Figure 18b also depicts DI-stimulated 
adenylate cyclase activity in the presence og GTP. The 
activity is defined as nrnoles cAMP/mg protein. 
Each value represents the mean ± the standard deviation of 
three individual experiments. The symbols • and •• indicate 
that values from control and ethanol-treated animals differ 
significantly at p<0.05 and p<0.01, respectively. 
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Figure 19. The effect of chronic ethanol treatment on 
adenylate cyclase activity in the frontal cortex 
of three-month-old rats. 
Figures 19a, 19b, 19c, and 19d depict basal adenylate 
cyclase activity of the frontal cortex in the absence of 
stimulatory chemicals (a), or in the presence of 100 µM GTP 
(b), 100 µM forskolin (c), or 10 nM sodium fluoride (NaF) 
(d). Figure 19b also depicts D-1 stimulated adenylate 
cyclase activity in the presence of GTP. The activity is 
defined as nmoles cAMP/mg protein. 
Each value represents the mean ± the standard deviation of 
three individual experiments. The symbols • and ** indicate 
that values from control and ethanol-treated animals differ 
significantly at p<0.05 and p<0.01, respectively. 
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one month results in significant alteration in adenylate 
cyclase activity in the nucleus accumbens of three-month-old 
Fisher 344 rats, although the adenylate cyclase activity of 
the striatum and the frontal cortex was not affected by 
ethanol treatment. 
Basal, Dl-stimulated, and D2-inhibited adenylate 
cyclase activities in the striatwn. were not significantly 
altered by chronic ethanol treatment (p>0.05). Striatal 
adenylate cyclase activity in the presence of forskolin, 
GTP, and sodium fluoride was not effected by ethanol 
treatment (p>0.05). 
In the nucleus accumbens, although basal adenylate 
cyclase activity was not significantly different in 
ethanol-treated animals (p>0.05), adenylate cyclase activity 
in the presence of 100 µM dopamine was significantly 
increased (70%) in ethanol-treated animals (p<0.05). 
Dl-stimulated adenylate cyclase activity was not 
significantly altered in the nucleus accumbens of 
ethanol-treated animals (p>0.05). Adenylate cyclase activity 
in the presence of forskolin, GTP, and sodium fluoride was 
not effected by ethanol treatment (p>0.05). Dopamine 
02-inhibited adenylate cyclase activity was not measurable 
in the nucleus accumbens. This finding concurs with the 
observations of Stoof and Verheijden (1986) and Kelly and 
Naharski (1987). 
Basal and Dl-stimulated adenylate cyclase activity was 
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not significantly altered in the frontal cortex of 
ethanol-treated animals (p>0.05). Since 02 sites were not 
measurable in the frontal cortex, 02-inhibited adenylate 
cyclase activity was not analyzed. Adenylate cyclase 
activity of the frontal cortex in the presence of forskolin, 
GTP, and sodium fluoride was not significantly altered in 
ethanol-treated animals (p>0.05). 
Analysis of G Proteins 
This study analyzed the effects of chronic ethanol 
treatment on the content of the G proteins in several brain 
regions. The a subunits of Gs and Go were measured using 
monoclonal antibodies directed against these subunits, Gia 
was not analyzed due to the unavailability of specific 
antibodies to this protein. The brain regions studied 
include the striatum, globus pallidus, and substantia nigra 
of the nigrostriatal pathway and the frontal cortex, nucleus 
accumbens, ventral pallidum, and the ventral tegmentum of 
the mesolimbic dopamine pathway. ~-Actin was analyzed as a 
control to monitor for equivalency for protein loading. 
The samples were separated on a 10% (v/v) sos-
polyacrylamide gel and the separated proteins were 
transferred to nitrocellulose filters. The filters were 
incubated with the antibody for the G proteins or actin 
(primary antibody), followed by incubation with [ 1~I)-IgG 
(secondary antibody). The filters were then exposed on film. 
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The autoradiograms for Gs, Go, and actin were scanned 
by a densitometer. Optical density (O.D.) values were 
assigned to each sample and these values were used to 
calculate ratios for Gs and Go relative to actin. Actin 
served as a control for differences in the loading of gel 
lanes. This allowed for a correction factor due to unequal 
protein loading onto the gel. The ratios were defined as 
arbitrary densitometer units (ADU). Three individual samples 
(control and ethanol) from each brain region were separated 
on a gel. Three additional individual samples were similarly 
analyzed. Thus, a total of six samples were analyzed for 
each brain region. 
The results of this study are shown in Figures 20 and 
21. Figure 20 depicts the ratio of ADU for Gs/actin in each 
brain region, while Figure 21 depicts the ratio of ADU for 
Go/actin. The values represent the mean ± the standard 
deviation of three individual samples separated on the same 
gel. Similar results were obtained from gels containing 
additional samples. In all brain regions analyzed, neither 
the Gs protein nor the Go protein were significantly altered 
{p>0.05). The results indicate that chronic ethanol exposure 
does not alter the protein content of the Gs or Go proteins 
in the striatum, globus pallidus, substantia nigra, nucleus 
accumbens, frontal cortex, ventral pallidum, and ventral 
tegmental area from three-month-old rats which consumed 
ethanol for one month prior to sacrifice. 
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Figure 20. The effects of chronic ethanol exposure on the 
protein content of Gs in three-month-old rats. 
Ethanol Control 
Brain Region 
Frontal Cortex 0.84 ± 0.14 0.80 ± 0.06 
Nucleus Accumbens 3.10 ± 0.49 3.13 ± 0.32 
Ventral Pallidum 4.55 ± 1.82 4.29 ± 1.80 
Ventral Tegmentum 2.79 ± 0.66 2.91 ± 0.08 
Stria tum 1.30 ± 0.51 1.28 ± 0.54 
Globus Pallidus 2.42 ± 0.99 2.66 ± 1.38 
Substantia Nigra 1.01 ± 0.05 1.07 ± 0.14 
------------------------------------------------------------
Each value represents the mean ± the standard deviation 
of the Gs/actin ratio in arbitrary densitometer units 
(ADU) obtained from three individual samples separated 
on the same gel. These results are similar to the 
results obtained from other gels. There was no 
significant difference in the protein content in 
similar samples of Gs from control and ethanol-treated 
rats in all brain regions analyzed (p>0.05). 
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Figure 21. The effects of chronic ethanol exposure on the 
protein content of Go in three-month-old rats. 
Ethanol Control 
Brain Region 
Frontal Cortex 3.33 ± 1.27 3.49 ± 1.16 
Nucleus Accumbens 8.44 ± 1.17 8.89 ± 1.59 
Ventral Pallidum 4.22 ± 0.45 4.11 ± 1. 02 
Ventral Tegmentum 4.85 ± 2.18 5.27 ± 2.61 
Stria tum 0.82 ± 0.17 0.88 ± 0.23 
Globus Pallidus 0.98 ± 0.03 0.94 ± 0.06 
Substantia Nigra 0.53 ± 0.23 0.51 ± 0.11 
------------------------------------------------------------
Each value represents the mean ± the standard deviation 
of the Go/actin ratio in arbitrary densitometer units 
{ADU) obtained from three individual samples separated 
on the same gel. These results are similar to the 
results obtained from other gels. There was no 
significant difference in the protein content in 
similar samples of Go from control and ethanol-treated 
rats in all brain regions analyzed {p>0.05). 
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Assessment of mRNA Levels of G Protein 
The mRNA levels of several G proteins were measured in 
brain regions of control and ethanol-treated animals. The 
cDNA probes for the a subunits of Gs, Go, Gi11 Gi2 , and Gi3 
(obtained from Dr. Randall Reed; Jones and Reed 1987) were 
used to analyze the mRNA levels of brain areas of the 
nigrostriatal and mesolimbic dopamine pathways. 
Total RNA was loaded onto Nytran filters utilizing a 
slot blot apparatus. The cDNA probes isolated from plasmids 
were subjected to a DNA digest and separated on a 0.7% (w/v) 
agarose gel to screen for purity (Figure 22). The cDNA 
probes were labeled with [32P]-CTP by random priming and 
hybridized to the filters. The filters were exposed to film 
to generate autoradiograms. 
The autoradiograms for the G proteins and actin were 
scanned by densitometer and ratios were calculated for each 
G protein (G protein/actin). These values were defined as 
arbitrary densitometer units (ADU). Slot blot analyses were 
repeated 3-5 times and G protein/actin ratios, obtained from 
scanning individual autoradiograms, were analyzed by the 
t-test for paired comparison to account for day to day 
differences in control ADU values. 
Typical slot blots for each G protein and actin are 
shown in Figures 23 to 27. The values listed in the legend 
represent the ratio of G protein to actin for each blot. 
There was a 20% decrease in mRNA levels for Go in the 
Figure 22. Analysis of DNA fragments after enzymatic 
cleavage. 
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The DNA probes for the G proteins were extracted from the 
plasmid, pGEM-2, and digested with the restriction enzyme, 
Eco RI. The DNA fragments were separated on a 0.7% (v/v) 
agarose gel to estimate the size of the cleavage products 
in order to determine the purity of preparation. 
Lane 1: Gi3 (3.1 kb) 
Lane 2: Gi2 (1. 8 kb) 
Lane 3: Gi1 (2. 0 kb) 
Lane 4: Go (2 .1 kb) 
Lane 5: Gs (0.7 and 1.1 kb) 
Lane 6: Size markers from HindIII and BamHI digest 
of phage T. 
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Figure 23. Ratio of mRNA for Gs/actin in 3-month-old control 
and ethanol-treated rats. 
Brain Region 
Frontal Cortex 
stria tum 
Nucleus Accumbens 
Globus Pallidus 
Substantia Nigra 
Ventral Tegmentum 
Ventral Pallidum 
Ethanol 
1. 84 
0.89 
1. 00 
1.32 
1.24 
0.60 
1.17 
Control 
1.63 
0.94 
0.85 
1.19 
1.33 
0.57 
1.30 
Each value represents the ratio of G protein/actin in 
arbitrary densitometer units (ADU) from a typical slot 
blot analysis. The differences in ratio values obtained 
from 3-5 paired experiments were statistically analyzed 
using the t-test for paired comparisons. There were no 
significant differences in Gs content in all brain 
regions analyzed (p>0.05). This figure represents a 
typical slot blot for Gs. Equal amounts of RNA were 
diluted to 1:10 and 1:1000 and all three dilutions 
were loaded onto the Nytran filter. The first sample of 
each set represents an ethanol-treated animal. 
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Figure 24. Ratio of mRNA for Go/actin in 3-month-old control 
and ethanol-treated animals. 
Brain Region 
Frontal Cortex 
stria tum 
Nucleus Accumbens 
Globus Pallidus 
Substantia Nigra 
Ventral Tegmentum 
Ventral Pallidum 
Ethanol 
1.05 
1.21 
1.07 
1.22 
0.92 .. 
1.00 
1.05 
Control 
1.05 
1.19 
1.11 
1.44 
1.14 
0.96 
1.08 
Each value represents the ratio of G protein/actin in 
arbitrary densitometer units (ADU) from a typical slot 
blot analysis. The differences in ratio values obtained 
from 3-5 paired experiments were statistically analyzed 
using the t-test for paired comparisons. There was a 
significant decrease in the Go content of the 
substantia nigra (p<0.01) (**).There were no 
significant differences in the other brain regions 
analyzed (p>0.05). This figure represents a typical 
slot blot for Go. Equal amounts of RNA were diluted to 
1:10 and 1:1000 and all three dilutions wereloaded onto 
the Nytran filter. The first sample of each set 
represents an ethanol-treated animal. 
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Figure 25. Ratio of mRNA for Gi1/actin in 3-month-old 
control and ethanol-treated animals. 
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Ethanol Control 
Brain Region 
Frontal Cortex 
Stria tum 
Nucleus Accumbens 
Globus Pallidus 
Substantia Nigra 
Ventral Tegmentum 
Ventral Pallidum 
0.87 
0.59 
0.84 
0.38 
0.90 
0.50 
0.70 
0.81 
0.67 
0.89 
0.47 
0.97 
0.54 
0.80 
Each value represents the ratio of G protein/actin in 
arbitrary densitometer units (ADU) from a typical slot 
blot analysis. The differences in ratio values obtained 
from 3-5 paired experiments were statistically analyzed 
using the t-test for paired comparisons. There were no 
significant differences in Gi1 content in all brain 
regions analyzed (p>0.05). This figure represnts a 
typical slot blot for Gil" Equal amounts of RNA were 
diluted to 1:10 and 1:1000 and all three dilutions were 
loaded onto the Nytran filter. The first sample of each 
set represents an ethanol-treated animal. 
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Figure 26. Ratio of mRNA for Gi2/actin in 3-month-old 
control and ethanol-treated animals. 
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Ethanol Control 
Brain Region 
Frontal Cortex 
Stria tum 
Nucleus Accumbens 
Globus Pallidus 
Substantia Nigra 
Ventral Tegmentum 
Ventral Pallidum 
0.83 
0.88 
0.63 
0.84 
1.36 
1.40 
1.20 
0.87 
0.78 
0.60 
0.95 
1.10 
1.25 
1.12 
Each value represents the ratio of G protein/actin in 
arbitrary densitometer units (ADU) from a typical slot 
blot analysis. The differences in ratio values obtained 
from 3-5 paired experiments were statistically analyzed 
using the t-test for paired comparisons. There were no 
significant differences in Gi2 content in all brain 
regions analyzed (p>0.05). This figure represents a 
typical slot blot for Gi2 • Equal amounts of RNA were 
diluted to 1:10 and 1:1000 and all three dilutions were 
loaded onto the Nytran filter. The first sample of each 
set represents an ethanol-treated animal. 
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Figure 27. Ratio of mRNA for Gi3/actin in 3-month-old 
control and ethanol-treated animals. 
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Ethanol Control 
Brain Region 
Frontal Cortex 
Stria tum 
Nucleus Accumbens 
Globus Pallidus 
Substantia Nigra 
Ventral Tegmentum 
Ventral Pallidum 
0. 71° 
0.83 
0.62 
0.73 
0.52 
1.13 
0. 31° 
0.53 
0.67 
0.48 
0.56 
0.63 
0.86 
0.22 
Each value represents the ratio of G protein/actin in 
arbitrary densitometer units (ADU) from slot blot 
analysis. The differences in ratio values obtained 
from 3-5 paired experiments were statistically analyzed 
using the t-test for paired comparisons. There was a 
significant increase in Gi3 content in the frontal 
cortex and ventral pallidum (p<0.05) (*).There was no 
significant differences in Gi3 content in the other 
brain regions analyzed (p>0.05). This figure 
represents a typical slot blot for Gi3 • Equal amounts 
of RNA were diluted to 1:10 and 1:1000 and 
loaded onto the Nytran filter. The first sample of each 
set represents an ethanol-treated animal. 
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substantia nigra (p<0.01). In all brain regions except the 
substantia nigra, there was a 30-40% increase in Gi3 but 
this difference was only significant in the frontal cortex 
and ventral pallidum (p<0.05). There were no significant 
differences in mRNA levels for Gs, Gi1 , and Gi2 in all brain 
regions analyzed. The results of this experiment indicate 
that three-month-old rats exposed to ethanol for one month 
displayed region specific alterations in the mRNA levels of 
Go and Gi3 , while the mRNA levels of Gs, Gi11 and Gi2 were 
not significantly changed. 
Cholesterol and Phospholipid Levels 
This study examined the cholesterol and phospholipid 
levels in synaptic plasma membranes prepared from whole 
brains of control and ethanol-treated rats. The results 
presented as the mean ± the standard deviation were compared 
for statistical significance using student's 't' test (Table 
2) • 
In comparison to control animals, there was a 42% 
increase in cholesterol levels (p<0.01), while the levels of 
phospholipid were not significantly different (p>0.05). 
There was also a significant increase (31%) in the ratio of 
cholesterol to phospholipid (p<0.05). This study 
demonstrates that consumption of an ethanol liquid diet for 
one month resulted in a significant increase in cholesterol 
levels and in the cholesterol/phospholipid ratio of synaptic 
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plasma membranes. 
Table 2 
Effects of Chronic Ethanol Consumption on Cholesterol and Phospholipids 
in Synaptic Plasma Membranes from 3-Month-Old Fisher 344 Rats 
Cholesterol 
(µmol/mg protein) 
Phospholipid 
(µmol/mg protein) 
Cholesterol/ 
Phospholipid 
Ethanol 
Control 
0.532 ± .068 .. 
0.375 ± .102 
1.017 ± .150 
0.948 ± .129 
o. 529 ± • 01a· 
0.403 ± .128 
Each value represents the mean ± the standard deviation 
of values obtained from individual synaptic membrane 
preparations from seven rats. The symbols • and .. indicate 
that values from control and ethanol-fed rats are 
significantly different at p<0.05 or p<0.01, respectively. 
I-' 
w 
0 
Summary 
Tables 3 and 4 represent a summary of the results of 
this research. 
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Table 3 
Components of the Mesolimbie Dopamine Pathway 
Frontal Nucleus Ventral Ventral 
Cortex Accumbens Pallidum Tegmentum 
Dopamine t NC t t 
DOPAC t .l. t t 
Dl Site ND ND 
G Protein 
(Gs) 
mRNA NC NC NC NC 
protein NC NC NC NC 
AC 
Activity: NC t 
D2 Site 
Spiperone ND NC ND ND 
NPA NC 
Conversion NC 
G Protein 
(Gi2) 
mRNA NC NC NC NC 
AC 
Activity: ND 
G Protein 
mRNA 
(Go) NC NC NC NC 
(Gil) NC NC NC NC 
(GiJ) i NC t NC 
protein 
(Go) NC NC NC NC 
NC: no change ND: not detected (-): not determined 
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Table 4 
Components of the Niqrostriatal Dopamine Pathway 
Stria tum Globus Substantia 
Pallidus Ni gr a 
Dopamine NC NC .J. 
DOPAC NC NC t 
Dl Site NC NC ND 
G Protein 
(Gs) 
mRNA NC NC NC 
protein NC NC NC 
AC 
Activity NC 
D2 Site 
Spiperone NC ND ND 
NPA NC 
Conversion NC 
G Protein 
(Gi2) 
mRNA NC NC NC 
AC 
Activity NC 
G Protein 
mRNA 
(Go) NC NC .J. 
(Gil) NC NC NC 
(Gi3) NC NC NC 
protein 
(Go) NC NC NC 
NC: no change ND: not detected (-): not determined 
CHAPTER V 
DISCUSSION 
The objective of this research was to examine the 
effect of chronic ethanol exposure on several components of 
the dopaminergic system. It was hypothesized that chronic 
ethanol consumption either alters the ability of the 
dopamine signal to effect cellular changes through signal 
transduction or alters the concentration of dopamine itself. 
These studies represented a comprehensive examination of the 
membrane components of the dopaminergic system. 
Specifically, the components analyzed included the dopamine 
Dl and 02 receptors, the guanine nucleotide binding proteins 
(G proteins), and adenylate cyclase activity. In addition, 
steady-state levels of dopamine and its metabolite, 
3,4-dihyroxyphenylacetic acid (DOPAC) were analyzed. These 
components were measured in brain regions associated with 
the nigrostriatal or mesolimbic dopamine pathways. 
Alterations in any of these components could contribute to 
ethanol-induced changes in motor activity or to the 
reinforcing effects of ethanol. 
These studies demonstrated that consumption of a 6.6% 
(v/v) ethanol-containing liquid diet for one month affected 
several components of the dopamine system in three-month-old 
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Fisher 344 rats. Specifically, there was a loss of Dl 
receptors in the frontal cortex and nucleus accumbens. In 
contrast, there was no change in Dl receptor affinity or 
density in the striatum and globus pallidus. In addition, 
the number and affinity of spiperone binding sites and the 
number of propylnorapomorphine high affinity sites, as well 
as their conversion from the high affinity state to the low 
affinity state in the striatum and nucleus accumbens were 
unchanged by chronic ethanol consumption. The concentrations 
of dopamine and DOPAC were increased at least two-fold in 
the frontal cortex, ventral pallidum, and ventral tegmental 
area, while the levels were unchanged in the striatum and 
globus pallidus. In the substantia nigra, dopamine 
concentration was decreased and that of DOPAC was increased. 
The dopamine concentration in the nucleus accumbens was 
normal, but that of DOPAC was decreased. An analysis of Gs 
and Go proteins demonstrated minimal, if any changes, in 
either protein content or mRNA levels in all brain regions 
analyzed. Concerning the inhibitory G proteins, the mRNA 
levels of Gi1 and Gi2 were unchanged in all brain regions, 
however, there was a trend towards an increase in the mRNA 
levels of Gi3 in all regions except the substantia nigra. 
This increase was only significant in the frontal cortex and 
ventral pallidum. In the frontal cortex and striatum, no 
change was seen in dopamine-sensitive adenylate cyclase 
activity, although Dl-stimulated adenylate cyclase activity 
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and Dl-stimulated adenylate cyclase activity in the presence 
of forskolin were increased in the nucleus accumbens. These 
results suggest a selective ethanol effect on several 
components of the dopamine system. 
Dopamine and DOPAC Concentrations 
This study examined the effects of chronic ethanol 
exposure on dopamine and DOPAC content in the striatum, 
globus pallidus, and substantia nigra which are components 
of the nigrostriatal pathway (Fibiger et al. 1974; Lindvall 
and Bjorkland 1979), and in the frontal cortex, nucleus 
accumbens, ventral pallidum, and ventral tegmental area 
which are components of the mesolimbic dopamine pathway 
{Lindvall et al. 1978; Nauta et al. 1978). Although, other 
laboratories have assessed dopamine and DOPAC content and 
turnover following acute ethanol exposure, this is the first 
extensive assessment of the effects of chronic ethanol 
consumption on the concentrations of dopamine and DOPAC in 
several brain regions. In the present study, the 
concentrations of dopamine ranged from 2.2 ng/mg protein in 
the frontal cortex to approximately 250 ng/mg protein in the 
striatum and globus pallidus in control rats. The 
concentrations of DOPAC ranged from 2.6 ng/mg protein in the 
frontal cortex to 234 ng/mg protein in the nucleus accumbens 
of control rats. Other investigators have reported dopamine 
and DOPAC concentrations are highest in the striatum and 
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lowest in frontal cortex (Fadda et al. 1980; Westerink 1983; 
Ehrenstrom and Johansson 1985; Haikala 1987; Wetherell et 
al. 1989). The dopamine concentrations in the nucleus 
accumbens and substantia nigra in the present study are 
comparable to values reported by Bacopoulous et al. (1978). 
Chronic ethanol consumption had a region-specific 
effect on dopamine and DOPAC levels in three-month-old 
Fisher 344 rats. In the frontal cortex, ventral pallidum, 
and ventral tegmental area, there was a two-fold increase in 
dopamine and DOPAC levels in the ethanol-treated animals. 
The dopamine content in the substantia nigra was slightly 
decreased but the level of DOPAC was increased two-fold. In 
the nucleus accumbens, dopamine concentration was not 
altered by chronic ethanol treatment, while that of DOPAC 
was decreased. Neither the dopamine nor DOPAC levels in the 
striatum and globus pallidus were affected by ethanol 
consumption. Some of the brain regions associated with the 
mesolimbic dopamine pathway are those affected by chronic 
ethanol treatment. In contrast, the content of dopamine and 
DOPAC in the striatum and globus pallidus which are 
components of the nigrostriatal pathway were not affected by 
chronic ethanol treatment. 
An increase in dopamine content as observed in the 
frontal cortex, ventral pallidum, and ventral tegmental area 
may reflect an increase in dopamine synthesis, a decrease in 
dopamine release, or a decrease in dopamine turnover. 
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Increased dopamine synthesis would occur if there were 
increased activity of tyrosine hydroxylase, the 
rate-limiting enzyme in the biosynthesis of the 
catecholamine neurotransmitters {Cooper et al. 1986). This 
enzyme can be activated by phosphorylation by any of at 
least three protein kinases: cAMP-dependent protein kinase, 
ca+2/calmodulin-dependent protein kinase, and 
ca+2/diacylglycerol-dependent protein kinase (Nestler and 
Greengard 1989). Phosphorylation of tyrosine hydroxylase 
increases its catalytic activity by increasing the affinity 
of the enzyme for its tetrahydropteridine cofactor and by 
decreasing its affinity for its end-product inhibitor 
{Cooper et al 1986). Ethanol may activate tyrosine 
hydroxylase by activating one or more protein kinase through 
an increased activation of second messenger systems (cAMP, 
phosphoinositide, ca+2) (Rabin and Molinoff 1981; Lynch and 
Littleton 1983; Hudspith et al. 1985; Saito et al. 1985; 
Gonzales et al. 1986; Messing et al. 1986; Dolin et al. 
1987). The present studies suggest the cAMP-dependent 
phosphorylation and activation of tyrosine hydroxylase may 
not occur in the frontal cortex since normal adenylate 
cyclase activity was found in this area. However, the 
present studies cannot exclude the possibility that ethanol 
may have increased tyrosine hydroxylase phosphorylation via 
altered phosphoinositide (IP3 ) formation or calcium (Ca+2) 
influx. 
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Within the ventral tegmental area, 02 receptors are 
reportedly autoreceptors on dendrites of dopaminergic 
neurons which project to the nucleus accumbens (Wang 1981; 
White and Wang 1984). In contrast, D2 receptors are lacking 
on ventral tegmental area dopaminergic cell bodies which 
project to the frontal cortex (Chiodo et al. 1984). In both 
projection areas of the ventral tegmental area (the frontal 
cortex and nucleus accumbens), 01 and 02 receptors are found 
postsynaptically (White and Wang 1984, 1986; Galloway et al. 
1986). In addition, D2 receptors are also found 
postsynaptically in the nucleus accumbens (White and Wang 
1986) . 
With the above receptor localization in mind, an 
elevation in ventral tegmental area dopamine and DOPAC may 
be indicative of an increase in the dendrodendritic release 
of dopamine. The increased release of dopamine, acting on 
the D2 autoreceptors, could inhibit firing of the projection 
from the ventral tegmental area to the nucleus accumbens. As 
a consequence of decreased firing, one would expect 
decreased release of dopamine, as suggested by the lower 
DOPAC levels in this region. In light of the apparent lack 
of a D2 autoreceptor in the ventral tegmental area on cells 
which project to the prefrontal cortex (Chiodo et al. 1984) 
and the finding of elevated cortical dopamine and DOPAC, a 
similar analogy cannot be made with the mesocortical system. 
On the other hand, dopamine was decreased in the 
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substantia nigra. Dopamine may be decreased if dopamine 
synthesis is decreased as a result of decreased activation 
(decreased phosphorylation} of tyrosine hydroxylase by the 
second messenger systems mentioned above. Alternatively, 
dopamine levels may be decreased if dopamine release is 
increased. Dopamine release could be increased by an 
ethanol-induced activation of second messenger systems which 
phosphorylate synapsin I. Synapsin I, a component of the 
regulation of neurotransmitter release, is associated with 
the synaptic vesicles located in the nerve terminal 
(Browning et al. 1985; De Camilli et al. 1986}. Synapsin I 
is phosphorylated by cAMP-dependent protein kinase and 
ca+2/calmodulin-dependent protein kinase. The 
dephosphorylated protein inhibits neurotransmitter release, 
whereas the phosphorylated protein facilitates release 
(Llinas et al. 1985). Consequently, phosphorylation of 
synapsin I could facilitate dopamine release and result in 
decreased dopamine levels as seen in the substantia nigra. 
If this explanation for a decrease in dopamine levels in the 
substantia nigra is valid, it would suggest that 
phosphorylation of synapsin I is not similarly affected in 
other brain regions which did not demonstrate a decrease in 
dopamine levels. 
It is also possible that ethanol may inhibit the 
enzymes responsible for the metabolic degradation of 
catecholamines: monoamine oxidase (MAO) and 
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catechol-0-methyltransferase (COMT). Differences in the 
concentration of OOPAC in the brain regions of 
ethanol-treated animals may reflect an ethanol-induced 
alteration in MAO activity. Presently, additional 
information is needed to substantiate this interpretation. 
In summary, three-month-old Fisher 344 rats fed an 
ethanol-containing diet for one month display unique 
regional responses. These differential effects for each 
brain region may reflect complex regulatory mechanisms 
specific for each region. 
Dopamine Receptors 
The present study provides information concerning the 
effects of chronic ethanol exposure on the dopamine Dl and 
02 receptors in rat brain. This is the first report that 
examines the 01 and D2 receptors in brain regions other than 
the striatum in chronically ethanol-treated rats. This is 
also the first report of the effects of ethanol on the 
conversion of the 02 receptor from the high affinity state 
to the low affinity state. 
Although the present study was unable to detect D2 
receptors in the frontal cortex, ventral pallidum, ventral 
tegmental area, globus pallidus and the substantia nigra, a 
more sensitive method, using quantitative autoradiography, 
detected 02 sites in these regions {Boyson et al. 1986; 
Charuchinda et al. 1987; Richfield et al. 1989). Similarly, 
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quantitative autoradiography has demonstrated 01 receptors 
in several brain regions in which these receptors were below 
the level of detectability for homogenate binding studies. 
These areas include the ventral pallidum, ventral tegmental 
area, and the substantia nigra (Richfield et al. 1987; 
1989). 
Total dopamine 01 sites were measured using the 
selective 01 antagonist, SCH 23390 (Billard et al. 1984). 
Binding studies indicate that [ 3H]-SCH 23390 binds 
stereospecifically with high affinity to a single site, the 
01 receptor site (Billard et al. 1984; Schulz et al. 1984). 
In the present study, the Kd values of control rats ranged 
from 0.3 nM in the globus pallidus to 2.0 nM in the frontal 
cortex. The Bmax values ranged from 0.2 pmol/mg protein in 
the frontal cortex to 0.8 pmol/mg protein in the nucleus 
accumbens. The Kd and Bmax values of this study are 
consistent with those in previous reports of Dl binding in 
the rat striatum (Billard et al. 1984; Schulz et al. 1985; 
Hess et al. 1986; Manik et al. 1988). 
The present study demonstrated regional alterations in 
dopamine 01 sites in ethanol-treated rats. A decrease in 01 
sites was observed in the nucleus accumbens and frontal 
cortex, while the 01 sites in the striatum and globus 
pallidus were not changed by ethanol treatment. The affinity 
of the SCH 23390 for 01 site was not significantly different 
in these four regions. Other studies have reported that 
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ethanol increases, decreases, or has no effect on striatal 
SCH 23390 Dl sites. Hietala et al. (1990) observed the 
number and affinity of Dl receptor sites in the frontal 
cortex and striatum were not significantly altered by 5 
weeks of ethanol treatment. However, Hruska (1988) reported 
a 40% increase in striatal Dl sites after 3 weeks of ethanol 
administration, while Lucchi et al. (1988) reported a 25% 
decrease in striatal Dl sites after 25 days of ethanol 
treatment. Both investigators observed no significant 
differences in the affinity of striatal Dl sites. The 
effects of ethanol exposure on Dl sites in other brain 
regions have not been reported. 
The discrepancies among the present report of striatal 
binding sites and previous findings are possibly explained 
by technical differences, specifically species, dose and 
mode of ethanol administration, or assay conditions. For 
example, Lucchi et al. (1988) administered 6% (v/v) ethanol 
in the drinking water to Sprague-Dawley rats. The mean daily 
intake of ethanol was 2-3 g/kg body weight. Hruska (1988) 
used a liquid diet with an ethanol concentration of 6.2% 
(v/v). Adult male Sprague-Dawley rats were placed on the 
diet for 14 or 21 days and the amount of ethanol consumed 
daily ranged from 12-17 g/kg body weight. Hietala et al. 
(1990) also used a liquid diet containing 6% (v/v) ethanol. 
Wister rats were maintained on the diet for 5 weeks. In the 
present study, male Fisher 344 rats were pair-fed a 6.6% 
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(v/v) ethanol-containing diet for 4 weeks. The average daily 
intake was 20-25 g/kg body weight. It is possible the 
different feeding models, length of treatment, daily intake, 
or species differences may account for the discrepancies in 
these findings. Nevertheless, the present findings 
corroborate some findings observed in other binding assays. 
Namely, ethanol treatment does not alter the affinity of the 
dopamine 01 receptor site and an ethanol effect in one 
region does not necessarily define the effect in all 
regions. 
It is interesting to note the selective decrease in 01 
sites in the nucleus accumbens and frontal cortex, brain 
areas which are components of the mesolimbic dopamine 
pathway (Lindvall et al. 1978; Nauta et al. 1978). The 
mesolimbic dopamine pathway is recognized as an important 
component of reward circuitry and has been implicated in the 
reinforcement of several drugs of abuse (Phillips and 
Fibiger 1978; Lyness et al. 1981; Bozarth and Wise 1981; 
Mathews and German 1984). Thus, changes in the dopamine 01 
receptors may in some way be associated with rewarding 
effects of ethanol and thus may potentially be involved with 
the development of ethanol dependence. 
Total dopamine 02 sites were measured using the 02 
antagonist, spiperone (Leyson et al. 1978). Spiperone binds 
specifically and with high affinity to a single class of 
dopamine 02 sites (Leslie and Bennett 1987). The Kd values 
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in this study ranged from 0.08 nM in the nucleus accumbens 
to 0.15 nM in the striatum of control animals. The Bmax 
values in the striatum were 0.1 pmol/mg protein. The Kd and 
Bmax values in this study are in agreement with reported Kd 
values and Bmax values of other binding assays in the rat 
striatum (Briley and Langer 1978; Leyson et al. 1978; Owen 
et al. 1979; List & Seeman 1981). Little information is 
available about the kinetics of spiperone binding, as 
measured by homogenate binding assays in the nucleus 
accumbens and frontal cortex. 
The density and affinity of dopamine 02 sites in the 
nucleus accumbens and striatum were not altered by ethanol 
exposure in this study. Similar to the reports of others 
regarding ethanol's effect on the 01 sites, various 
laboratories have observed an increase, decrease, or no 
change in 02 sites after ethanol treatment. Hietala et al. 
(1990) demonstrated that the affinity and number of striatal 
02 sites, measured by [3H]-spiperone, were not significantly 
altered by 3 or 5 weeks of ethanol treatment. In addition, 
the specific binding of [3H]-haloperidol to striatal 02 
sites was unaffected in rats treated with ethanol for 11-15 
days (Muller et al. 1980). In contrast, Hruska (1988) 
reported an increase (15-20%) in striatal D2 sites measured 
by spiperone after 3 weeks of ethanol treatment, while 
Lucchi et al. (1988) observed a decrease (27%) in these 
sites after 25 days of ethanol exposure. Furthermore, 
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Syvalahti et al. (1988) found a decrease (38%) in the number 
of striatal 02 sites in rats treated with ethanol for 32 
weeks. As stated previously, the difference in findings may 
be attributed to technical differences including species, 
dose and duration of ethanol treatment, and assay 
conditions. 
The effect of chronic ethanol exposure on the high 
affinity state of the dopamine 02 site and its ability to 
convert from the high affinity state to the low affinity 
state were analyzed with the 02 agonist, 
propylnorapomorphine (Creese et al. 1979; Titeler and Seeman 
1979). This 02 agonist binds with high affinity to an 
apparently homogeneous receptor population, representing the 
high affinity agonist binding site {Sibley et al. 1982). 
Guanine nucleotides decrease the binding capacity for 
[ 3H)-propylnorapomorphine by inducing a conformational 
change in the high affinity state of the receptor {Sibley et 
al. 1982), a mechanism involving the guanine nucleotide 
regulatory proteins {G proteins) {Boeynaems and Dumont 
1975). 
This is the first report that examines agonist binding 
in brain regions of control and ethanol-treated rats. The Kd 
values of control animals ranged from 0.1 nM in the striatum 
to 0.4 nM in the nucleus accumbens. In the presence of GTP, 
the Kd values ranged from 0.2 nM in the striatum to 0.7 nM 
in the nucleus accumbens. Reported Kd values range from 0.2 
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nM in bovine anterior pituitary to 1.5 nM bovine striatum 
{Sibley et al. 1982; Creese et al. 1979). In the presence of 
GTP, the Kd value reported in the anterior pituitary was 0.3 
nM (Sibley et al. 1982). The Bmax values of control animals 
in the present study ranged from 0.1 pmol/mg protein in the 
nucleus accumbens to 0.2 pmol/mg protein in the striatum and 
in the presence of GTP, the Bmax values ranged from 0.07 
pmol/mg protein in the nucleus accumbens to 0.1 pmol/mg 
protein in the striatum. 
In the present study, approximately 50% of the striatal 
02 high affinity sites were converted to the low affinity 
state in the presence of GTP; in the nucleus accumbens 
approximately 35% of the sites were converted in the 
presence of GTP. Sibley et al. {1982) reported a 50% 
conversion rate in the anterior pituitary. Chronic ethanol 
treatment did not alter the binding of 
[ 3H]-propylnorapomorphine to the high affinity site or the 
conversion of the 02 high affinity site to the low affinity 
site in the striatum and nucleus accumbens. 
In summary, this study demonstrated that 
three-month-old Fisher 344 rats exposed to ethanol for the 
month displayed a selective ethanol effect on the dopamine 
receptors. There was a significant decrease in the number of 
01 sites in the nucleus accumbens and frontal cortex while 
the 01 sites in the striatum and globus pallidus were not 
altered. In these four regions, the affinity of SCH 23390 
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was not affected by ethanol treatment. The density and 
affinity of the dopamine 02 sites in the striatum and 
nucleus accumbens were not significantly different in 
ethanol-treated rats. Also ethanol exposure did not change 
the affinity, number, or conversion of the 02 high affinity 
site. 
The number of 01 receptors was decreased in both the 
nucleus accumbens and frontal cortex of ethanol-fed rats. 
Although a decrease in cortical 01 receptor number could be 
potentially explained as a compensatory down regulation in 
response to the increased dopamine release (increased OOPAC) 
in the cortex, this explanation cannot explain the decrease 
in 01 receptors in the nucleus accumbens since OOPAC is 
decreased in this area. Alternative explanations for the 
decreased number of dopamine receptors are: 1) receptor 
desensitization, 2) agonist-induced endocytosis, 3) 
decreased gene transcription. For example, ethanol may 
induce receptor desensitization of the 01 receptor or may 
inhibit transcription of the gene for the 01 receptor, 
resulting in the loss of 01 receptor sites. It is also 
possible that the selective effect of ethanol on 01 
receptors in distinct brain areas may reflect a different 
cellular localization of the 01 and 02 receptors. 
Molecular mechanisms of receptor desensitization have 
been described using the ~-adrenergic receptor as a model 
(Sibley et al. 1987). A similar mechanism may exist for 
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other receptor types including the dopamine Dl receptor. 
Receptors assume an altered conformation during 
desensitization. This conformational change is promoted by 
covalent receptor modification. Phosphorylation plays a role 
in desensitizing receptors linked to the G proteins (Klein 
et al. 1989). Receptors may be phosphorylated by a variety 
of protein kinases but a novel cAMP-independent protein 
kinase (PARK) appears to be involved in the homologous 
desensitization of the P-adrenergic receptor (Benovic et al. 
1986). This enzyme only phosphorylates the agonist-occupied 
form of the receptor. When a cell is stimulated by a 
P-adrenergic agonist, PARK is translocated from the cytosol 
to the plasma membrane where it phosphorylates the 
agonist-occupied receptor {Strasser et al. 1986). The 
phosphorylated receptor is uncoupled from adenylate cyclase 
and sequestered within the cell into low density membrane 
vesicles. Within the vesicle, the receptor is 
dephosphorylated by a phosphoprotein phosphatase and then is 
functionally regenerated. When the agonist is removed, the 
receptor is redistributed to the plasma membrane. PARK may 
serve as a nonspecific adenylate cyclase-coupled receptor 
kinase and may play a role in a generalized mechanism for 
homologous desensitization for several receptors including 
the dopamine receptors. 
The loss of dopamine Dl receptors in the nucleus 
accumbens and frontal cortex may be explained by an ethanol 
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effect on the mechanism described above. Ethanol may promote 
receptor phosphorylation via an increased activation of one 
or more second messenger pathway, which in turn may activate 
one or more protein kinases. An activated protein kinases 
would increase the phosphorylation state of the receptor, 
maintaining the receptor in an inactive form. on the other 
hand, ethanol may inhibit phosphatase activity, thus 
maintaining the phosphorylated state of the receptor and in 
turn, inhibit the recycling of the receptors into the plasma 
membrane resulting in a loss of receptors. Presently, 
additional information regarding ethanol's effects on this 
mechanism is needed to substantiate this interpretation. 
Another mechanism which may account for the down 
regulation of receptors is receptor-mediated endocytosis. 
Ligand-induced receptor degradation occurs when the 
endosomes containing the receptors fuse with lysosomes 
(Chuang et al. 1982). It is possible that ethanol mediated 
changes in dopamine concentrations or other 
neurotransmitters levels may promote agonist-induced 
receptor degradation resulting in receptor down-regulation. 
Adaptive changes in receptor density may also be 
regulated at the level of gene transcription. Ethanol may 
alter the activation or inhibition of transcriptional 
factors that control the rate of transcription. A decrease 
in transcription may result in a decreased receptor number. 
The recent availability of cDNA probes for the dopamine 
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receptors will provide a means to examine this mechanism of 
receptor regulation. 
It is interesting to note the selective loss of the Dl 
receptors in the nucleus accumbens and frontal cortex. It is 
possible the Dl and 02 receptors are differentially 
regulated within each brain region or cell type at the level 
of gene transcription. It is possible that the genes for the 
01 and 02 receptors require at least one tissue specific 
transcriptional factor in order for transcription to occur. 
Although, the precise pharmacological actions of ethanol are 
unknown, however, the differential responses to ethanol 
reveal the complex neuronal interactions involved in normal 
physiological activity. 
Regardless of the cause of the decreased number of 01 
receptors in the frontal cortex and nucleus accumbens, it is 
doubtful whether this decrease is responsible for altered 
cellular function because in the presence of a saturating 
concentration of GTP dopamine-stimulated adenylate cyclase 
activity was not altered in either region. Additional 
components of this signal transduction pathway, namely the 
synthesis and concentration of Gsa as well as the basal, 
NaF, and forskolin-stimulated adenylate cyclase activity 
were unaltered in these regions from ethanol-fed rats. 
Consequently, the loss of 01 receptors from the frontal 
cortex and nucleus accumbens may represent a loss of spare 
receptors. 
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Adenylate Cyclase Activity 
In the present study, cAMP levels were assessed as an 
indicator of adenylate cyclase activity. The response of 
adenylate cyclase to stimulation by forskolin, GTP, and 
sodium fluoride was also analyzed as a means to define the 
site of ethanol's action. Basal, Dl-stimulated, and 
02-inhibited adenylate cyclase activity was not altered in 
the striatum of ethanol-treated animals. There was no change 
in the stimulation of striatal adenylate cyclase activity by 
forskolin, GTP, and sodium fluoride. Similarly, adenylate 
cyclase activity in the frontal cortex was not altered by 
ethanol treatment. In contrast, basal adenylate cyclase 
activity in the presence of dopamine was significantly 
increased in the nucleus accumbens of ethanol-treated 
animals, Dl-stimulated activity and basal adenylate cyclase 
activity in the presence of forskolin or sodium fluoride 
were unchanged in this region. It is possible that there was 
a sufficient amount of GTP in the tissue resulting in the 
stimulation of adenylate cyclase by dopaminej however, 
further studies will be necessary to determine the site of 
this ethanol effect. 
In studies by other laboratories, chronic ethanol 
treatment generally produced a decrease in adenylate cyclase 
activity. Dopamine-stimulated and norepinephrine-stimulated 
adenylate cyclase activity was reduced in the striatum and 
cerebral cortex, respectively (Tabakoff and Hoffman 1979; 
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Lucchi et al. 1983; Saito et al. 1987). The stimulation of 
adenylate cyclase by various agonists and agents acting 
through Gs or adenylate cyclase also was decreased after 
chronic ethanol exposure (Saito et al. 1987). Studies in 
cultured cells demonstrated a similar response, a decrease 
in agonist-stimulated adenylate cyclase after chronic 
ethanol treatment (Richelson et al. 1986; Rabin 1990). In 
contrast, Rabin et al. (1987) reported an increased response 
to dopamine-stimulated, GTP-stimulated, and sodium fluoride-
stimulated adenylate cyclase activity in the striatum of 
chronic ethanol-treated rats. The discrepancies among the 
present study and other studies may be attributed to 
different laboratory protocols. For example, some studies 
examined adenylate cyclase activity in ethanol-withdrawn 
animals which may not represent the effects of chronic 
ethanol exposure. Mode of ethanol administration, dose of 
ethanol, or animal species also may contribute to these 
different findings. 
An increase in cAMP levels may be the result of 
increased levels of adenylate cyclase. Ethanol may alter the 
activation of one or more transcription factors which 
regulate the gene for adenylate cyclase. Alternatively, 
ethanol may inhibit the degradation of either the mRNA or 
the protein for adenylate cyclase. Such alterations would 
result in an increased synthesis of cAMP. 
Another possible explanation for increased cAMP levels 
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may be decreased phosphodiesterase activity. 
Phosphodiesterase hydrolyzes the phosphodiester linkage of 
cAMP terminating the biological activity of adenylate 
cyclase. As stated previously, ethanol may alter the 
activation of the transcription factors regulating the 
expression of the gene for phosphodiesterase. Decreased 
phosphodiesterase levels may result in increased levels of 
cAMP. Phosphodiesterase is regulated by cAMP-dependent 
protein kinase (Northup et al. 1989). Phosphorylation of 
this enzyme decreases its affinity for calmodulin, thereby 
decreasing its activation. Alternately the phosphorylation 
state of phosphodiesterase may be modulated via the 
dopamine-stimulated phosphorylation and activation of 
DARPP-32, potent inhibitor of protein phosphatase-1 
(Hemmings et al. 1989). Inhibition of protein phosphatase-1 
would maintain phosphodiesterase in its phosphorylated 
inactive state. 
G Proteins 
In the present study, mRNA and protein levels of the a 
subunit of several G proteins were assessed by slot blot 
analysis and Western analysis. In all brain regions 
surveyed, the mRNA levels of the a subunits of Gs, Gi11 and 
Gi2 were not altered by ethanol exposure. There were 
significant differences in the mRNA levels of Go in the 
substantia nigra and Gi3 in the frontal cortex and ventral 
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pallidum. The protein levels of the a subunits of Gs and Go 
were not affected by ethanol treatment. The 01 stimulation 
of adenylate cyclase appears to involve Gs, whereas 02 
inhibition of adenylate cyclase may be coupled to Gi2 
(Senogles et al. 1990). Ethanol-induced alterations of 
dopamine-sensitive adenylate cyclase activity may not be 
mediated through the G proteins since ethanol does not 
affect G protein synthesis. Although there was a decrease 
(20%) in the Go mRNA level in the substantia nigra, the 
protein level of Go in the substantia nigra was not altered. 
A change in mRNA levels of this magnitude may not result in 
differences in protein levels. 
The results of this study concur with findings reported 
concerning G protein content in the cerebral cortices of 
chronically treated mice (Hoffman and Tabakoff 1990). The 
investigators observed no significant alterations in the 
levels of the a subunits of the Gs and Go proteins. However, 
studies of ethanol-treated culture cell lines differ. 
Mochley-Rosen and colleagues (1988) demonstrated decreases 
in mRNA and protein levels of the a, subunit in chronic 
ethanol-treated NG 108-15 cells. Charness and colleagues 
(1988) reported a decrease in the content of the a, subunit 
in NG 108-15 and NlE-115 cell lines, but not in the N18TG2 
cell line. They also found a dose-dependent increase in the 
ai subunit in the NlE-115 cell line with no change in the NG 
108-15 and N18TG2 cell lines. In the present study, there 
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was a significant increase in the mRNA levels of Gi3 in the 
frontal cortex and ventral pallidum which may result in an 
increase in the protein content as observed by Charness et 
al. (1988). 
In theory the presently observed ethanol-induced 
changes in adenylate cyclase activity may involve 
alterations of the synthesis of the a subunits of the G 
proteins. Mochley-Rosen and colleagues (1988) suggest the 
quantity of a, is the rate-limiting step in the activation 
of adenylate cyclase. However, this hypothesis is not 
supported by the present study because the mRNA and protein 
levels of a 1 were not altered by ethanol exposure. Hoffman 
and Tabakoff (1990) suggest the possibility that chronic 
ethanol exposure causes posttranslational modification of 
the a subunit that may alter its interaction with receptors 
and effectors. In the present study, this possibilty could 
not be tested utilizing the selected experimental procedure. 
In summary, three-month-old rats exposed to ethanol for 
one month display regional specific changes in G protein 
mRNA levels, but protein content of Gs and Go were not 
altered. Although there were small changes in the mRNA 
levels of Go and Gi3 , these differences may not affect the 
overall function of the G proteins. The results of this 
study suggest ethanol's action may be at the level of 
adenylate cyclase rather than at the level of the G 
proteins. 
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Cholesterol/Phospholipid Ratio of Synaptic Plasma Membranes 
Although a significant increase in the 
cholesterol/phospholipid ratio of synaptic plasma membranes 
was observed, it is unlikely that this membrane change was 
responsible for the observed changes in components of the 
dopaminergic system. Whereas the present studies report a 
decrease in dopamine Dl receptor number in certain brain 
areas, earlier studies from this laboratory have shown that 
Dl receptor number is not significantly affected by changing 
the cholesterol/phospholipid ratio (Maguire and Druse 1989). 
In contrast, artificial elevation of the 
cholesterol/phospholipid ratio does inhibit dopamine-
stimulated adenylate cyclase (Maguire and Druse 1989), while 
the ethanol-induced increase in membrane cholesterol did not 
inhibit this enzyme in any brain region examined. Thus, the 
observed changes in membrane-associated components of the 
dopaminergic systems appear to be caused by factors other 
than changes in the membrane cholesterol content. 
Concluding Remarks 
The results of the present studies have demonstrated 
that several components of the dopaminergic system in 
three-old-month Fisher 344 rats are altered after one month 
of chronic ethanol exposure. Those brain areas which are 
affected are associated with the mesolimbic dopamine 
pathway. There was a loss of the 01 dopamine receptor in the 
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nucleus accumbens and frontal cortex of chronic 
ethanol-treated rats. Dopamine and DOPAC levels were 
increased two-fold in the frontal cortex, ventral pallidum, 
and ventral tegmental area, while DOPAC levels were 
decreased in the nucleus accumbens of chronic 
ethanol-treated rats. In the nucleus accumbens, there was an 
increase in basal adenylate cyclase activity in the presence 
of dopamine. 
These changes in the brain regions of the mesolimbic 
dopamine pathway are notable because this pathway is a 
component of the reward circuitry (Phillips and Fibiger 
1978). Several drug self-stimulation studies suggest that 
dopamine neurons in the accumbens and prefrontal cortex play 
a critical role in the reinforcement of cocaine (Roberts and 
Koob 1980; Goeders and Smith 1986). It is also possible the 
mesolimbic dopamine neurons may be involved in the rewarding 
effects of ethanol (Koob and Weiss 1990; Lewis and June 
1990; McBride et al. 1990; Samson et al. 1990). 
In three-month-old Fisher 344 rats fed an 
ethanol-containing diet for one month prior to sacrifice, 
specific components of the mesolimbic and mesocortical 
dopamine systems were significantly altered. Whether these 
changes are translated into behavioral abnormalities is not 
known. Although, it does not appear that the observed 
changes in receptor number contribute to signal transduction 
in regards to the adenylate cyclase pathway, we cannot rule 
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out the possibilty that other dopamine-sensitive signal 
transduction pathways may be altered. Furthermore, it is not 
known whether the observed changes are readily reversed upon 
withdrawal of the ethanol diet or whether they represent the 
first stages of a potential neurotoxicity. 
The differential responses of each brain region to 
chronic ethanol may reflect different mechanisms of 
regulation as discussed previously. In addition, regulation 
through other neurotransmitter systems should be considered 
as a possible explanation for ethanol's selective effects. 
For example, GABA, serotonin, and neurotensin may have a 
role in the regulation of the dopamine system (Mereu and 
Gessa 1985; Nemeroff and Cain 1985; Erwin and Korte 1988; 
Galloway 1990). Thus, alterations in components of the 
dopamine system may be secondary to the effects of ethanol 
on other neurotransmitter systems. Consequently, ethanol's 
unique effect on a given neurotransmitter may reflect the 
interaction of effects produced on a number of interrelated 
pathways. 
CHAPTER VI 
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